

09/15/03 8:00 AM

L Number	Hits	Search Text	DB	Time stamp
-	17726	vascula\$10 near3 (permeab\$8 or leak\$6) or edema\$	USPAT; US-PGPUB	2003/11/18 09:43
-	520884	src or yes	USPAT; US-PGPUB	2003/11/18 09:43
-	3918	(vascula\$10 near3 (permeab\$8 or leak\$6) or edema\$) and (src or yes)	USPAT; US-PGPUB	2003/11/18 10:02
-	25	(vascula\$10 near3 (permeab\$8 or leak\$6) or edema\$) same (src or yes)	USPAT; US-PGPUB	2003/11/18 09:44
-	2001	(src or yes) near10 (inhibit\$8 or decreas\$8)	USPAT; US-PGPUB	2003/11/18 10:02
-	85	(vascula\$10 near3 (permeab\$8 or leak\$6) or edema\$) and ((src or yes) near10 (inhibit\$8 or decreas\$8))	USPAT; US-PGPUB	2003/11/18 10:02

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:26:06 ON 18 NOV 2003

=> fil .bec
COST IN U.S. DOLLARS
SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 2.31 2.31

FILES 'MEDLINE, SCISEARCH, LIFESCI, BIOTECHDS, BIOSIS, EMBASE, HCAPLUS, NTIS,
ESBIOBASE, BIOTECHNO, WPIDS' ENTERED AT 15:32:24 ON 18 NOV 2003
ALL COPYRIGHTS AND RESTRICTIONS APPLY. SEE HELP USAGETERMS FOR DETAILS.

11 FILES IN THE FILE LIST

=> s vascula?(3a) (permeab? or leak?) or edema?
FILE 'MEDLINE'

335676 VASCULA?
90357 PERMEAB?
36170 LEAK?
6889 VASCULA?(3A) (PERMEAB? OR LEAK?)
73887 EDEMA?
L1 79495 VASCULA?(3A) (PERMEAB? OR LEAK?) OR EDEMA?

FILE 'SCISEARCH'

205268 VASCULA?
93454 PERMEAB?
45760 LEAK?
7575 VASCULA?(3A) (PERMEAB? OR LEAK?)
33919 EDEMA?
L2 40352 VASCULA?(3A) (PERMEAB? OR LEAK?) OR EDEMA?

FILE 'LIFESCI'

22797 VASCULA?
16769 PERMEAB?
5227 LEAK?
1145 VASCULA?(3A) (PERMEAB? OR LEAK?)
4053 EDEMA?
L3 5043 VASCULA?(3A) (PERMEAB? OR LEAK?) OR EDEMA?

FILE 'BIOTECHDS'

2930 VASCULA?
2866 PERMEAB?
873 LEAK?
92 VASCULA?(3A) (PERMEAB? OR LEAK?)
248 EDEMA?
L4 332 VASCULA?(3A) (PERMEAB? OR LEAK?) OR EDEMA?

FILE 'BIOSIS'

2029487 VASCULA?
89242 PERMEAB?
32491 LEAK?
8727 VASCULA?(3A) (PERMEAB? OR LEAK?)
55549 EDEMA?
L5 62760 VASCULA?(3A) (PERMEAB? OR LEAK?) OR EDEMA?

FILE 'EMBASE'

345158 VASCULA?
76516 PERMEAB?
33336 LEAK?
6409 VASCULA?(3A) (PERMEAB? OR LEAK?)
73871 EDEMA?
L6 78917 VASCULA?(3A) (PERMEAB? OR LEAK?) OR EDEMA?

FILE 'HCAPLUS'
 125710 VASCULA?
 194179 PERMEAB?
 75898 LEAK?
 6163 VASCULA? (3A) (PERMEAB? OR LEAK?)
 28226 EDEMA?
L7 33285 VASCULA? (3A) (PERMEAB? OR LEAK?) OR EDEMA?

FILE 'NTIS'
 2412 VASCULA?
 12708 PERMEAB?
 14830 LEAK?
 84 VASCULA? (3A) (PERMEAB? OR LEAK?)
 778 EDEMA?
L8 846 VASCULA? (3A) (PERMEAB? OR LEAK?) OR EDEMA?

FILE 'ESBIOBASE'
 60751 VASCULA?
 47190 PERMEAB?
 8568 LEAK?
 1976 VASCULA? (3A) (PERMEAB? OR LEAK?)
 6263 EDEMA?
L9 7965 VASCULA? (3A) (PERMEAB? OR LEAK?) OR EDEMA?

FILE 'BIOTECHNO'
 32809 VASCULA?
 17766 PERMEAB?
 4507 LEAK?
 1246 VASCULA? (3A) (PERMEAB? OR LEAK?)
 3768 EDEMA?
L10 4835 VASCULA? (3A) (PERMEAB? OR LEAK?) OR EDEMA?

FILE 'WPIDS'
 18162 VASCULA?
 100370 PERMEAB?
 128530 LEAK?
 405 VASCULA? (3A) (PERMEAB? OR LEAK?)
 2003 EDEMA?
L11 2355 VASCULA? (3A) (PERMEAB? OR LEAK?) OR EDEMA?

TOTAL FOR ALL FILES
L12 316185 VASCULA? (3A) (PERMEAB? OR LEAK?) OR EDEMA?

=> S SRC or yes

FILE 'MEDLINE'
 13330 SRC
 3299 YES
L13 16299 SRC OR YES

FILE 'SCISEARCH'
 12632 SRC
 2959 YES
L14 15334 SRC OR YES

FILE 'LIFESCI'
 5159 SRC
 440 YES
L15 5446 SRC OR YES

FILE 'BIOTECHDS'
 217 SRC
 40 YES
L16 247 SRC OR YES

FILE 'BIOSIS'
 13040 SRC
 1809 YES
L17 14540 SRC OR YES

FILE 'EMBASE'
 9661 SRC
 2290 YES
L18 11707 SRC OR YES

FILE 'HCAPLUS'
 13093 SRC
 1970 YES
L19 14685 SRC OR YES

FILE 'NTIS'
 1989 SRC
 328 YES
L20 2316 SRC OR YES

FILE 'ESBIOBASE'
 6455 SRC
 642 YES
L21 6968 SRC OR YES

FILE 'BIOTECHNO'
 6804 SRC
 375 YES
L22 7004 SRC OR YES

FILE 'WPIDS'
 696 SRC
 886 YES
L23 1521 SRC OR YES

TOTAL FOR ALL FILES
L24 96067 SRC OR YES

=> s l12 and l24
FILE 'MEDLINE'
L25 41 L1 AND L13

FILE 'SCISEARCH'
L26 48 L2 AND L14

FILE 'LIFESCI'
L27 9 L3 AND L15

FILE 'BIOTECHDS'
L28 0 L4 AND L16

FILE 'BIOSIS'
L29 37 L5 AND L17

FILE 'EMBASE'
L30 32 L6 AND L18

FILE 'HCAPLUS'
L31 55 L7 AND L19

FILE 'NTIS'
L32 1 L8 AND L20

FILE 'ESBIOBASE'

L33 20 L9 AND L21

FILE 'BIOTECHNO'

L34 8 L10 AND L22

FILE 'WPIDS'

L35 27 L11 AND L23

TOTAL FOR ALL FILES

L36 278 L12 AND L24

=> dup rem 136

PROCESSING COMPLETED FOR L36

L37 128 DUP REM L36 (150 DUPLICATES REMOVED)

=> d tot

L37 ANSWER 1 OF 128 HCAPLUS COPYRIGHT 2003 ACS on STN DUPLICATE 1
TI Preparation of phosphorus-substituted pyridopyrimidones as therapeutic agents

SO PCT Int. Appl., 164 pp.

CODEN: PIXXD2

IN Metcalf, Chester A., III; Shakespeare, William C.; Sawyer, Tomi K.; Wang, Yihan; Bohacek, Regine

AN 2003:5788 HCAPLUS

DN 138:56078

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|--|----------|-----------------|----------|
| WO 2003000270 | A1 | 20030103 | WO 2002-US19605 | 20020621 |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| US 2003100572 | A1 | 20030529 | US 2002-177520 | 20020621 |

L37 ANSWER 2 OF 128 HCAPLUS COPYRIGHT 2003 ACS on STN DUPLICATE 2

TI Preparation of phosphorus-substituted quinolines as therapeutic agents

SO PCT Int. Appl., 146 pp.

CODEN: PIXXD2

IN Metcalf, Chester A., III; Shakespeare, William C.; Sawyer, Tomi K.; Wang, Yihan; Bohacek, Regine

AN 2003:5784 HCAPLUS

DN 138:56077

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|--|----------|-----------------|----------|
| WO 2003000266 | A1 | 20030103 | WO 2002-US19535 | 20020621 |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| US 2003114486 | A1 | 20030619 | US 2002-177500 | 20020621 |

L37 ANSWER 3 OF 128 HCAPLUS COPYRIGHT 2003 ACS on STN DUPLICATE 3
TI Preparation of phosphorus-substituted idolinones as therapeutic agents
SO PCT Int. Appl., 230 pp.
CODEN: PIXXD2

IN Shakespeare, William C.; Sawyer, Tomi K.; Metcalf, Chester A., III; Wang, Yihan; Bohacek, Regine
AN 2003:5770 HCAPLUS

DN 138:56076

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| PI WO 2003000251 | A1 | 20030103 | WO 2002-US19769 | 20020621 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,
TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| US 2003130234 | A1 | 20030710 | US 2002-177472 | 20020621 |

L37 ANSWER 4 OF 128 HCAPLUS COPYRIGHT 2003 ACS on STN DUPLICATE 4
TI Preparation of phosphorus-substituted quinazolines as therapeutic agents
SO PCT Int. Appl., 188 pp.

CODEN: PIXXD2

IN Wang, Yihan; Metcalf, Chester A., III; Shakespeare, William C.; Sawyer, Tomi K.; Bohacek, Regine
AN 2003:5719 HCAPLUS

DN 138:73379

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| PI WO 2003000188 | A2 | 20030103 | WO 2002-US19633 | 20020621 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,
TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| US 2003100573 | A1 | 20030529 | US 2002-177595 | 20020621 |

L37 ANSWER 5 OF 128 HCAPLUS COPYRIGHT 2003 ACS on STN DUPLICATE 5
TI Preparation of phosphorus-substituted pyrazolo- and pyrrolopyrimidines as therapeutic agents
SO PCT Int. Appl., 165 pp.

CODEN: PIXXD2

IN Shakespeare, William C.; Sawyer, Tomi K.; Metcalf, Chester A., III; Wang, Yihan; Bohacek, Regine; Sundaramoorthi, Rajeswari
AN 2003:5718 HCAPLUS

DN 138:56075

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| PI WO 2003000187 | A2 | 20030103 | WO 2002-US19632 | 20020621 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, | | | | |

TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
US 2003114467 A1 20030619 US 2002-177563 20020621

L37 ANSWER 6 OF 128 HCAPLUS COPYRIGHT 2003 ACS on STN DUPLICATE 6
TI Preparation of phosphorus-substituted phenylamino-pyrimidines as
therapeutic agents
SO PCT Int. Appl., 203 pp.
CODEN: PIXXD2
IN Metcalf, Chester A., III; Shakespeare, William C.; Sawyer, Toni K.; Wang,
Yihan; Bohacek, Regine
AN 2003:5717 HCAPLUS
DN 138:56074
PATENT NO. KIND DATE APPLICATION NO. DATE
----- ---- ----- -----
PI WO 2003000186 A2 20030103 WO 2002-US19631 20020621
WO 2003000186 A3 20030410
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,
TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

L37 ANSWER 7 OF 128 HCAPLUS COPYRIGHT 2003 ACS on STN
TI Pyrazolopyrimidine and furopyrimidine protein kinase inhibitors and their
therapeutic use
SO PCT Int. Appl., 94 pp.
CODEN: PIXXD2
IN Hirst, Gavin C.; Arnold, Lee D.; Burchat, Andrew; Wishart, Neil;
Calderwood, David; Wada, Carol K.; Michaelides, Michael R.; Ji, Zhiqin;
Muckey, Melanie
AN 2003:777596 HCAPLUS
DN 139:272922
PATENT NO. KIND DATE APPLICATION NO. DATE
----- ---- ----- -----
PI WO 2003080064 A1 20031002 WO 2003-US8950 20030321
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD,
RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC,
NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG
US 2003199525 A1 20031023 US 2002-103098 20020321

L37 ANSWER 8 OF 128 HCAPLUS COPYRIGHT 2003 ACS on STN
TI Preparation of phosphorus-substituted pyridopyridimines as therapeutic
agents
SO PCT Int. Appl., 151 pp.
CODEN: PIXXD2
IN Metcalf, Chester A., III; Shakespeare, William C.; Sawyer, Toni K.; Wang,
Yihan; Bohacek, Regine
AN 2003:5665 HCAPLUS

DN 138:56073
 PATENT NO. KIND DATE APPLICATION NO. DATE
 ----- ----- -----
 PI WO 2003000011 A2 20030103 WO 2002-US19768 20020621
 WO 2003000011 A3 20030320
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 DM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,
 TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 US 2003105115 A1 20030605 US 2002-176790 20020621

L37 ANSWER 9 OF 128 HCPLUS COPYRIGHT 2003 ACS on STN
 TI Preparation of 4-aminopyrrolopyrimidines as protein kinase inhibitors
 SO U.S. Pat. Appl. Publ., 93 pp., Cont.-in-part of U.S. 6,001,839.
 CODEN: USXXCO
 IN Calderwood, David; Arnold, Lee; Mazdiyasni, Hormoz; Hirst, Gavin C.; Deng,
 Bojuan B.; Johnston, David N.; Rafferty, Paul; Tometzki, Gerald B.;
 Twigger, Helen L.; Munschauer, Rainer
 AN 2003:777394 HCPLUS
 DN 139:292260
 PATENT NO. KIND DATE APPLICATION NO. DATE
 ----- ----- -----
 PI US 2003187001 A1 20031002 US 1999-399083 19990917
 US 6001839 A 19991214 US 1998-42702 19980317

L37 ANSWER 10 OF 128 HCPLUS COPYRIGHT 2003 ACS on STN
 TI Preparation of pyrrolopyrimidines as tyrosine kinase inhibitors
 SO U.S. Pat. Appl. Publ., 166 pp., Cont.-in-part of Appl. No. PCT/US99/21560.
 CODEN: USXXCO
 IN Hirst, Gavin C.; Calderwood, David; Munschauer, Rainer; Arnold, Lee D.;
 Johnston, David N.; Rafferty, Paul
 AN 2003:633320 HCPLUS
 DN 139:180075
 PATENT NO. KIND DATE APPLICATION NO. DATE
 ----- ----- -----
 PI US 2003153752 A1 20030814 US 2000-537167 20000329
 WO 2000017203 A1 20000330 WO 1999-US21560 19990917
 W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,
 CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
 IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD,
 MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
 SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ,
 BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
 DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
 CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 ZA 2001002204 A 20020318 ZA 2001-2204 20010316

L37 ANSWER 11 OF 128 WPIDS COPYRIGHT 2003 THOMSON DERWENT on STN
 TI New quinoline derivatives useful for treating proliferative disorders e.g.
 cancer, and diseases mediated by kinase.
 PI WO 2003000705 A1 20030103 (200320)* EN 111p C07F009-60
 RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ
 NL OA PT SD SE SL SZ TR TZ UG ZM ZW
 W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK
 DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR
 KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT
 RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM

ZW
US 2003105065 A1 20030605 (200339) A61K031-675
IN BOHACEK, R; METCALF, C A; SAWYER, T K; SHAKESPEARE, W C; WANG, Y

L37 ANSWER 12 OF 128 WPIDS COPYRIGHT 2003 THOMSON DERWENT on STN
TI Treatment of myocardial infarction comprising use of composition containing tyrosine kinase inhibitor.
PI US 2003130209 A1 20030710 (200362)* 37p A61K031-7048
IN CHERESH, D A; ELICEIRI, B; PAUL, R

L37 ANSWER 13 OF 128 SCISEARCH COPYRIGHT 2003 THOMSON ISI on STN DUPLICATE 7
TI Regulation of vascular endothelial growth factor production by Leydig cells in vitro: The role of protein kinase A and mitogen-activated protein kinase cascade
SO BIOLOGY OF REPRODUCTION, (MAY 2003) Vol. 68, No. 5, pp. 1663-1673.
Publisher: SOC STUDY REPRODUCTION, 1603 MONROE ST, MADISON, WI 53711-2021 USA.
ISSN: 0006-3363.
AU Anand R J K; Paust H J; Altenpohl K; Mukhopadhyay A K (Reprint)
AN 2003:400292 SCISEARCH

L37 ANSWER 14 OF 128 HCAPLUS COPYRIGHT 2003 ACS on STN
TI Involvement of integrins and **Src** in tauroursodeoxycholate-induced and swelling-induced choleresis
SO Gastroenterology (2003), 124(5), 1476-1487
CODEN: GASTAB; ISSN: 0016-5085
AU Haeussinger, Dieter; Kurz, Anna Kordelia; Wettstein, Matthias; Graf, Dirk;
Vom Dahl, Stephan; Schliess, Freimut
AN 2003:400763 HCAPLUS
DN 139:111587

L37 ANSWER 15 OF 128 SCISEARCH COPYRIGHT 2003 THOMSON ISI on STN
TI Differential alpha v integrin-mediated Ras-ERK signaling during two pathways of angiogenesis
SO JOURNAL OF CELL BIOLOGY, (1 SEP 2003) Vol. 162, No. 5, pp. 933-943.
Publisher: ROCKEFELLER UNIV PRESS, 1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021 USA.
ISSN: 0021-9525.
AU Hood J D; Frausto R; Kiosses W B; Schwartz M A; Cheresh D A (Reprint)
AN 2003:783166 SCISEARCH

L37 ANSWER 16 OF 128 HCAPLUS COPYRIGHT 2003 ACS on STN
TI SS~~e~~CKS regulates angiogenesis and tight junction formation in blood-brain barrier
SO Nature Medicine (New York, NY, United States) (2003), 9(7), 900-906
CODEN: NAMEFI; ISSN: 1078-8956
AU Lee, Sae-Won; Kim, Woo Jean; Choi, Yoon Kyung; Song, Hyun Seok; Son, Myung Jin; Gelman, Irwin H.; Kim, Yung-Jin; Kim, Kyu-Won
AN 2003:497020 HCAPLUS
DN 139:274263

L37 ANSWER 17 OF 128 MEDLINE on STN DUPLICATE 8
TI A selective and oral small molecule inhibitor of vascular epithelial growth factor receptor (VEGFR)-2 and VEGFR-1 inhibits neovascularization and **vascular permeability**.
SO JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, (2003 Sep) 306 (3) 838-45.
Journal code: 0376362. ISSN: 0022-3565.
AU Patel Neela; Sun Li; Moshinsky Deborah; Chen Hui; Leahy Kathleen M; Le Phuong; Moss Katherine G; Wang Xueyan; Rice Audie; Tam Danny; Laird A Douglas; Yu Xiaoming; Zhang Qingling; Tang Cho; McMahon Gerald; Howlett Anthony
AN 2003423675 MEDLINE

- L37 ANSWER 18 OF 128 MEDLINE on STN DUPLICATE 9
TI **Src** Family Kinase Activity Is Required for Signal Transducer and Activator of Transcription 3 and Focal Adhesion Kinase Phosphorylation and Vascular Endothelial Growth Factor Signaling in Vivo and for Anchorage-dependent and -independent Growth of Human Tumor Cells.
SO Mol Cancer Ther, (2003 May) 2 (5) 461-9.
Journal code: 101132535. ISSN: 1535-7163.
AU Laird A Douglas; Li Guangmin; Moss Katherine G; Blake Robert A; Broome Martin A; Cherrington Julie M; Mendel Dirk B
AN 2003226904 IN-PROCESS
- L37 ANSWER 19 OF 128 MEDLINE on STN DUPLICATE 10
TI Myosin light chain kinase-dependent microvascular hyperpermeability in thermal injury.
SO SHOCK, (2003 Oct) 20 (4) 363-8.
Journal code: 9421564. ISSN: 1073-2322.
AU Huang Qiaobing; Xu Wenjuan; Ustinova Elena; Wu Mack; Childs Ed; Hunter Felicia; Yuan Sarah
AN 2003442060 IN-PROCESS
- L37 ANSWER 20 OF 128 EMBASE COPYRIGHT 2003 ELSEVIER INC. ALL RIGHTS RESERVED. on STN DUPLICATE 11
TI [Prevalence of fibromyalgia in diabetes mellitus and obesity]. PREVALENZA DELLA SINDROME FIBROMIALGICA NEL DIABETE MELLITO E NELL'OBESITA.
SO Recenti Progressi in Medicina, (1 Apr 2003) 94/4 (163-165).
Refs: 27
ISSN: 0034-1193 CODEN: RPMDAN
AU Patucchi E.; Fatati G.; Puxeddu A.; Coaccioli S.
AN 2003312989 EMBASE
- L37 ANSWER 21 OF 128 MEDLINE on STN DUPLICATE 11
TI Requirement of different signaling pathways mediated by insulin-like growth factor-I receptor for proliferation, invasion, and VPF/VEGF expression in a pancreatic carcinoma cell line.
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, (2003 Feb 28) 302 (1) 46-55.
Journal code: 0372516. ISSN: 0006-291X.
AU Zeng Huiyan; Datta Kaustubh; Neid Matthias; Li Jinping; Parangi Sareh; Mukhopadhyay Debabrata
AN 2003082640 MEDLINE
- L37 ANSWER 22 OF 128 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN DUPLICATE 11
TI Mechanisms of signal transduction in **vascular permeability**: Potential targets.
SO Pathophysiology of Haemostasis and Thrombosis, (September 2003) Vol. 33, No. Suppl. 1, pp. 5-6. print.
Meeting Info.: Second International Conference on Thrombosis and Haemostasis Issues in Cancer. Bergamo, Italy. September 19-21, 2003.
ISSN: 1424-8832 (ISSN print).
AU Eliceiri, Brian [Reprint Author]
AN 2003:535681 BIOSIS
- L37 ANSWER 23 OF 128 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN DUPLICATE 11
TI Leukocyte **Src** kinases are required for host defense during *S. aureus* pneumonia in mice.
SO FASEB Journal, (March 2003) Vol. 17, No. 4-5, pp. Abstract No. 161.24. <http://www.fasebj.org/>. e-file.
Meeting Info.: FASEB Meeting on Experimental Biology: Translating the Genome. San Diego, CA, USA. April 11-15, 2003. FASEB.
ISSN: 0892-6638 (ISSN print).
AU Sayers, Benjamin P. [Reprint Author]; Makita, Hironi; Lowell, Clifford A.; Doerschuk, Claire M.
AN 2003:381733 BIOSIS

- L37 ANSWER 24 OF 128 NTIS COPYRIGHT 2003 NTIS on STN
 TI Blocking Vascular Hyperpermeability, the Initiation Step of Tumor
 Angiogenesis Inhibits Mammary Tumor. Final rept. 30 Sep 2000-30 Sep
 2002.
 NR ADA411357/XAB
 17p; Oct 2002
 PD Oct 2002
 AU Mukhopadhyay, D.
 AN 2003(17):00010 NTIS
- L37 ANSWER 25 OF 128 HCAPLUS COPYRIGHT 2003 ACS on STN DUPLICATE 12
 TI Preparation of 3-(azahetero)aryl-1H-pyrazolo[3,4-d]pyrimidin-3-amines as
 protein kinase inhibitors with antiangiogenic properties
 SO PCT Int. Appl., 867 pp.
 CODEN: PIXXD2
 IN Hirst, Gavin C.; Rafferty, Paul; Ritter, Kurt; Calderwood, David; Wishart,
 Neil; Arnold, Lee D.; Friedman, Michael M.
 AN 2002:793426 HCAPLUS
 DN 137:310925

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|--|----------|-----------------|----------|
| WO 2002080926 | A1 | 20021017 | WO 2002-US9104 | 20020322 |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,
TJ, TM | | | |
| RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| US 2002156081 | A1 | 20021024 | US 2001-815310 | 20010322 |

L37 ANSWER 26 OF 128 HCAPLUS COPYRIGHT 2003 ACS on STN DUPLICATE 13
 TI Preparation of 3-(azahetero)aryl-1H-pyrazolo[3,4-d]pyrimidin-3-amines as
 protein kinase inhibitors with antiangiogenic properties
 SO PCT Int. Appl., 440 pp.
 CODEN: PIXXD2
 IN Hirst, Gavin C.; Rafferty, Paul; Ritter, Kurt; Calderwood, David; Wishart,
 Neil; Arnold, Lee D.; Friedman, Michael M.
 AN 2002:754390 HCAPLUS
 DN 137:263056

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|--|----------|-----------------|----------|
| WO 2002076986 | A1 | 20021003 | WO 2002-US8996 | 20020322 |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,
TJ, TM | | | |
| RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |

L37 ANSWER 27 OF 128 HCAPLUS COPYRIGHT 2003 ACS on STN
 TI Preparation of 3-(azahetero)aryl-1H-pyrazolo[3,4-d]pyrimidin-3-amines as
 protein kinase inhibitors with antiangiogenic properties
 SO U.S. Pat. Appl. Publ., 426 pp., Cont.-in-part of U.S. Ser. No. 663,780.
 CODEN: USXXCO
 IN Hirst, Gavin C.; Rafferty, Paul; Ritter, Kurt; Calderwood, David; Wishart,

AN Neil; Arnold, Lee D.; Friedman, Michael M.
 DN 2002:814851 HCAPLUS
 137:310930

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--------|---|------|----------|-----------------|----------|
| PI | US 2002156081 | A1 | 20021024 | US 2001-815310 | 20010322 |
| | WO 2002080926 | A1 | 20021017 | WO 2002-US9104 | 20020322 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,
TJ, TM | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| L37 | ANSWER 28 OF 128 HCAPLUS COPYRIGHT 2003 ACS on STN | | | | |
| TI | Preparation of 3-(hetero)aryl pyrazoles with 4,5(3,4)-bicyclic ring fusion
as protein kinase inhibitors | | | | |
| SO | U.S., 69 pp., Cont.-in-part of WO 2000 27,822. | | | | |
| CODEN: | USXXAM | | | | |
| IN | Doyle, Kevin J.; Rafferty, Paul; Steele, Robert W.; Wilkins, David J.;
Arnold, Lee D.; Hockley, Michael; Ericsson, Anna M.; Iwasaki, Nobuhiko;
Ogawa, Nobuo | | | | |
| AN | 2002:770129 HCAPLUS | | | | |
| DN | 137:279184 | | | | |
| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
| PI | US 6462036 | B1 | 20021008 | US 2000-573366 | 20000517 |
| | WO 2000027822 | A2 | 20000518 | WO 1999-US26105 | 19991104 |
| | WO 2000027822 | A3 | 20000810 | | |
| | W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,
CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,
SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| | WO 2001087846 | A2 | 20011122 | WO 2001-US16153 | 20010517 |
| | WO 2001087846 | A3 | 20020321 | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,
RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,
UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| | EP 1289525 | A2 | 20030312 | EP 2001-937553 | 20010517 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| | JP 2003533514 | T2 | 20031111 | JP 2001-584242 | 20010517 |
| L37 | ANSWER 29 OF 128 WPIDS COPYRIGHT 2003 THOMSON DERWENT on STN | | | | |
| TI | New pyrazole derivatives as c-Jun N-terminal kinase 3, Src , and
Lck protein kinase inhibitors, useful for treating e.g.
glomerulonephritis, ulcerative colitis and osteoporosis. | | | | |
| PI | WO 2002092573 A2 20021121 (200320)* EN 38p C07D231-00
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ | | | | |

NL OA PT SD SE SL SZ TR TZ UG ZM ZW
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK
DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR
KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT
RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM
ZW

US 2003144309 A1 20030731 (200354) C07D417-14
IN MOON, Y

L37 ANSWER 30 OF 128 WPIDS COPYRIGHT 2003 THOMSON DERWENT on STN
TI New heterocyclic derivatives useful in treating e.g. hypercalcemia or
osteoporosis are protein kinase inhibitors.
PI WO 2002079197 A1 20021010 (200308)* EN 115p C07D405-04
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ
NL OA PT SD SE SL SZ TR TZ UG ZM ZW
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK
DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR
KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT
RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM
ZW

US 2003087922 A1 20030508 (200337) A61K031-506
IN BETHIEL, R S; COCHRAN, J; MOON, Y; NANTHAKUMAR, S; BETHIEL, R

L37 ANSWER 31 OF 128 WPIDS COPYRIGHT 2003 THOMSON DERWENT on STN
TI Use of a composition comprises water- and/or fat-soluble cytosolic pollen
extract and optionally pistils, optionally combined with royal jelly and
vitamin E in the manufacture of a medicament for treating **edema**.
PI WO 2002017941 A1 20020307 (200235)* EN 22p A61K035-78
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ
NL OA PT SD SE SL SZ TR TZ UG ZW
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK
DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR
KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO
RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AU 2001084581 A 20020313 (200249) A61K035-78
EP 1313496 A1 20030528 (200336) EN A61K035-78
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT
RO SE SI TR

IN HEDMAN, C; KAERNERUD, L; WINTER, K

L37 ANSWER 32 OF 128 MEDLINE on STN DUPLICATE 14
TI Deciphering vascular endothelial cell growth factor/**vascular**
permeability factor signaling to **vascular**
permeability. Inhibition by atrial natriuretic peptide.
SO JOURNAL OF BIOLOGICAL CHEMISTRY, (2002 Nov 15) 277 (46) 44385-98.
Journal code: 2985121R. ISSN: 0021-9258.
AU Pedram Ali; Razandi Mahnaz; Levin Ellis R
AN 2002666128 MEDLINE

L37 ANSWER 33 OF 128 HCPLUS COPYRIGHT 2003 ACS on STN
TI Uncoupling of the cholera toxin-GM1 ganglioside receptor complex from
endocytosis, retrograde Golgi trafficking, and downstream signal
transduction by depletion of membrane cholesterol
SO Journal of Biological Chemistry (2002), 277(18), 16249-16256
CODEN: JBCHA3; ISSN: 0021-9258
AU Wolf, Anne A.; Fujinaga, Yukako; Lencer, Wayne I.
AN 2002:361086 HCPLUS
DN 136:351585

L37 ANSWER 34 OF 128 MEDLINE on STN DUPLICATE 15
TI Distinct signals via Rho GTPases and **Src** drive shape changes by
thrombin and sphingosine-1-phosphate in endothelial cells.
SO JOURNAL OF CELL SCIENCE, (2002 Jun 15) 115 (Pt 12) 2475-84.
Journal code: 0052457. ISSN: 0021-9533.

- AU Vouret-Craviari Valerie; Bourcier Christine; Boulter Etienne; van Obberghen-Schilling Ellen
AN 2002303882 MEDLINE
- L37 ANSWER 35 OF 128 HCAPLUS COPYRIGHT 2003 ACS on STN
TI **Src**-dependent, neutrophil-mediated vascular hyperpermeability and β -catenin modification
SO American Journal of Physiology (2002), 283(6, Pt. 1), C1745-C1751
CODEN: AJPHAP; ISSN: 0002-9513
AU Tinsley, John H.; Ustinova, Elena E.; Xu, Wenjuan; Yuan, Sarah Y.
AN 2002:975066 HCAPLUS
DN 138:351650
- L37 ANSWER 36 OF 128 SCISEARCH COPYRIGHT 2003 THOMSON ISI on STN
TI Critical involvement of p38 MAP kinase in pertussis toxin-induced cytoskeletal reorganization and lung permeability
SO FASEB JOURNAL, (JUL 2002) Vol. 16, No. 9, pp. 1064-1076.
Publisher: FEDERATION AMER SOC EXP BIOL, 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA.
ISSN: 0892-6638.
AU Garcia J G N (Reprint); Wang P Y; Schaphorst K L; Becker P M; Borbiev T;
Liu F; Birukova A; Jacobs K; Bogatcheva N; Verin A D
AN 2002:741943 SCISEARCH
- L37 ANSWER 37 OF 128 MEDLINE on STN DUPLICATE 16
TI Novel interaction of cortactin with endothelial cell myosin light chain kinase.
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, (2002 Nov 8) 298 (4) 511-9.
Journal code: 0372516. ISSN: 0006-291X.
AU Dudek Steven M; Birukov Konstantin G; Zhan Xi; Garcia Joe G N
AN 2002649628 MEDLINE
- L37 ANSWER 38 OF 128 SCISEARCH COPYRIGHT 2003 THOMSON ISI on STN
TI Loss of placental growth factor protects mice against **vascular permeability** in pathological conditions
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, (12 JUL 2002) Vol. 295, No. 2, pp. 428-434.
Publisher: ACADEMIC PRESS INC ELSEVIER SCIENCE, 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA.
ISSN: 0006-291X.
AU Luttun A; Brusselmans K; Fukao H; Tjwa M; Ueshima S; Herbert J M; Matsuo O; Collen D; Carmeliet P (Reprint); Moons L
AN 2002:607834 SCISEARCH
- L37 ANSWER 39 OF 128 SCISEARCH COPYRIGHT 2003 THOMSON ISI on STN
TI Targeted delivery of mutant Raf kinase to neovessels causes tumor regression
SO COLD SPRING HARBOR SYMPOSIA ON QUANTITATIVE BIOLOGY, (JUL 2002) Vol. 67, pp. 285-291.
Publisher: COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT, 500 SUNNYSIDE BLVD, WOODBURY, NY 11797-2924 USA.
ISSN: 0091-7451.
AU Hood J D (Reprint); Cheresh D A
AN 2003:553531 SCISEARCH
- L37 ANSWER 40 OF 128 MEDLINE on STN DUPLICATE 17
TI **Src**-mediated coupling of focal adhesion kinase to integrin alpha(v)beta5 in vascular endothelial growth factor signaling.
SO JOURNAL OF CELL BIOLOGY, (2002 Apr 1) 157 (1) 149-60.
Journal code: 0375356. ISSN: 0021-9525.
AU Eliceiri Brian P; Puente Xose S; Hood John D; Stupack Dwayne G; Schlaepfer David D; Huang Xiaozhu Z; Sheppard Dean; Cheresh David A
AN 2002215352 MEDLINE

- L37 ANSWER 41 OF 128 EMBASE COPYRIGHT 2003 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
TI Fibromyalgia in diabetes mellitus and obesity: A simple questionnaire as a tool to recognize fibromyalgia in metabolic disorders.
SO Journal of Functional Syndromes, (2002) 2/2 (123-126).
Refs: 26
ISSN: 1591-0989 CODEN: JFSOBV
AU Coaccioli S.; Patucchi E.; Fatati G.; Capito G.; Puxeddu A.
AN 2003141936 EMBASE
- L37 ANSWER 42 OF 128 MEDLINE on STN
TI Differential displacement of classical cadherins by VE-cadherin.
SO Cell Commun Adhes, (2002 Mar-Apr) 9 (2) 103-15.
Journal code: 101096596. ISSN: 1541-9061.
AU Jaggi Meena; Wheelock Margaret J; Johnson Keith R
AN 2002724750 MEDLINE
- L37 ANSWER 43 OF 128 MEDLINE on STN
TI Breathless.
SO EMERGENCY MEDICAL SERVICES, (2002 Apr) 31 (4) 87.
Journal code: 0431735. ISSN: 0094-6575.
AU Dominguez Orlando J Jr
AN 2002227157 MEDLINE
- L37 ANSWER 44 OF 128 MEDLINE on STN
TI **Src** kinase becomes preferentially associated with the VEGFR, KDR/Flk-1, following VEGF stimulation of vascular endothelial cells.
SO BMC Biochem, (2002 Dec 31) 3 (1) 32.
Journal code: 101084098. ISSN: 1471-2091.
AU Chou Mary T; Wang Jing; Fujita Donald J
AN 2003060410 MEDLINE
- L37 ANSWER 45 OF 128 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
DUPLICATE 18
TI **Src** kinase becomes preferentially associated with the VEGFR, KDR/Flk-1, following VEGF stimulation of vascular endothelial cells.
SO BMC Biochemistry, (December 31, 2002) Vol. 3, No. 32 Cited January 31, 2003. <http://www.biomedcentral.com/1472-2091>. online.
AU Chou, Mary T.; Wang, Jing; Fujita, Donald J. [Reprint Author]
AN 2003:118800 BIOSIS
- L37 ANSWER 46 OF 128 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
TI Intravitreal Triamcinolone for Diabetic Macular **Edema**: A Clinical and Fluorescein Angiographic Study.
SO ARVO Annual Meeting Abstract Search and Program Planner, (2002) Vol. 2002, pp. Abstract No. 3458. cd-rom.
Meeting Info.: Annual Meeting of the Association For Research in Vision and Ophthalmology. Fort Lauderdale, Florida, USA. May 05-10, 2002.
AU Bakri, S. J. [Reprint Author]; Beer, P. M.
AN 2003:175043 BIOSIS
- L37 ANSWER 47 OF 128 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
TI UTILIZATION OF DIFFERENT CELLULAR MECHANISMS TO SCREEN FOR NEUROPROTECTIVE COMPOUNDS FOR STROKE.
SO Society for Neuroscience Abstract Viewer and Itinerary Planner, (2002) Vol. 2002, pp. Abstract No. 694.16. <http://sfn.scholarone.com>. cd-rom.
Meeting Info.: 32nd Annual Meeting of the Society for Neuroscience. Orlando, Florida, USA. November 02-07, 2002. Society for Neuroscience.
AU Pong, K. [Reprint Author]; Bramlett, D. R. [Reprint Author]; Zaleska, M. M. [Reprint Author]
AN 2003:325713 BIOSIS
- L37 ANSWER 48 OF 128 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN

- TI Contour Map of Diabetic Macular **Edema**.
 SO ARVO Annual Meeting Abstract Search and Program Planner, (2002) Vol. 2002,
 pp. Abstract No. 541. cd-rom.
 Meeting Info.: Annual Meeting of the Association For Research in Vision
 and Ophthalmology. Fort Lauderdale, Florida, USA. May 05-10, 2002.
 AU Schwartz, B. [Reprint Author]; Takamoto, T.; Zarbin, M.; Bhagat, N.;
 Young, L.; Rosen, R.
 AN 2003:142467 BIOSIS
- L37 ANSWER 49 OF 128 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
 TI Cardioprotection by blockade of **Src** activity in models of acute
 myocardial infarction.
 SO Circulation, (November 5, 2002) Vol. 106, No. 19 Supplement, pp. II-314.
 print.
 Meeting Info.: Abstracts from Scientific Sessions. Chicago, IL, USA.
 November 17-20, 2002. American Heart Association.
 ISSN: 0009-7322 (ISSN print).
 AU Weber, Alberto [Reprint Author]; Kirchmair, Rudolf [Reprint Author];
 Bosch-Marce, Marta [Reprint Author]; Yoon, Young-sup [Reprint Author];
 Wecker, Andrea [Reprint Author]; Kearney, Marianne [Reprint Author];
 Hanley, Allison [Reprint Author]; Ma, Hong [Reprint Author]; Cheresh,
 David; Losordo, Douglas W. [Reprint Author]
 AN 2003:77573 BIOSIS
- L37 ANSWER 50 OF 128 HCAPLUS COPYRIGHT 2003 ACS on STN DUPLICATE 19
 TI Pyrrolopyrimidines as tyrosine kinase inhibitors
 SO PCT Int. Appl., 453 pp.
 CODEN: PIXXD2
 IN Hirst, Gavin C.; Calderwood, David; Munschauer, Rainer; Arnold, Lee D.;
 Johnston, David N.; Rafferty, Paul
 AN 2001:730744 HCAPLUS
 DN 135:288790
- | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|-----------------|----------|
| PI WO 2001072751 | A1 | 20011004 | WO 2000-US8593 | 20000329 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR,
CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,
ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE,
SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,
ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
- L37 ANSWER 51 OF 128 HCAPLUS COPYRIGHT 2003 ACS on STN DUPLICATE 20
 TI Angiogenesis and **vascular permeability** modulators and
 inhibitors
 SO PCT Int. Appl., 132 pp.
 CODEN: PIXXD2
 IN Cheresh, David A.; Eliceiri, Brian; Paul, Robert
 AN 2001:472531 HCAPLUS
 DN 135:81944
- | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|-----------------|----------|
| PI WO 2001045751 | A1 | 20010628 | WO 2000-US35396 | 20001222 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,
ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, | | | | |

| | | | | |
|---------------|---|----------|----------------|----------|
| EP 1250155 | A1 | 20021023 | EP 2000-990365 | 20001222 |
| R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | |
| BR 2000016547 | A | 20021029 | BR 2000-16547 | 20001222 |
| JP 2003518077 | T2 | 20030603 | JP 2001-546690 | 20001222 |
| NO 2002003036 | A | 20020722 | NO 2002-3036 | 20020621 |

L37 ANSWER 52 OF 128 HCAPLUS COPYRIGHT 2003 ACS on STN DUPLICATE 21
 TI Preparation of pyrazolopyrimidines as protein kinase inhibitors
 SO PCT Int. Appl., 527 pp.
 CODEN: PIXXD2
 IN Hirst, Gavin C.; Calderwood, David; Wishart, Neil; Rafferty, Paul; Ritter,
 Kurt; Arnold, Lee D.; Friedman, Michael M.
 AN 2001:208278 HCAPLUS
 DN 134:252353
 PATENT NO. KIND DATE APPLICATION NO. DATE
 ----- ---- ----- -----
 PI WO 2001019829 A2 20010322 WO 2000-US25468 20000915
 WO 2001019829 A3 20010927
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
 HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
 LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
 SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
 YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
 CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 EP 1212327 A2 20020612 EP 2000-963554 20000915
 EP 1212327 B1 20030820
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL
 BR 2000014073 A 20020716 BR 2000-14073 20000915
 JP 2003509428 T2 20030311 JP 2001-523406 20000915
 AT 247657 E 20030915 AT 2000-963554 20000915
 NO 2002001328 A 20020521 NO 2002-1328 20020318
 BG 106586 A 20030131 BG 2002-106586 20020405

L37 ANSWER 53 OF 128 HCAPLUS COPYRIGHT 2003 ACS on STN
 TI Preparation of tricyclic pyrazole derivatives as tyrosine kinase
 inhibitors for treatment of angiogenesis-related diseases
 SO PCT Int. Appl., 183 pp.
 CODEN: PIXXD2
 IN Doyle, Kevin J.; Rafferty, Paul; Steele, Robert W.; Wilkins, David J.;
 Arnold, Lee D.; Hockley, Michael; Ericsson, Anna M.; Iwasaki, Nobuhiko;
 Ogawa, Nobuo
 AN 2001:851123 HCAPLUS
 DN 136:5985
 PATENT NO. KIND DATE APPLICATION NO. DATE
 ----- ---- ----- -----
 PI WO 2001087846 A2 20011122 WO 2001-US16153 20010517
 WO 2001087846 A3 20020321
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,
 RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,
 UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 US 6462036 B1 20021008 US 2000-573366 20000517
 EP 1289525 A2 20030312 EP 2001-937553 20010517

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
JP 2003533514 T2 20031111 JP 2001-584242 20010517

L37 ANSWER 54 OF 128 HCAPLUS COPYRIGHT 2003 ACS on STN
TI Substituted 1,4-dihydroindeno[1,2-c]pyrazoles as inhibitors of tyrosine kinase
SO U.S., 36 pp., Cont.-in-part of U.S. Ser. No. 541,336.
CODEN: USXXAM
IN Doyle, Kevin; Rafferty, Paul; Steele, Robert; Turner, Allyson; Wilkins, David; Arnold, Lee
AN 2001:719086 HCAPLUS
DN 135:272953
PATENT NO. KIND DATE APPLICATION NO. DATE
----- ----- -----
PI US 6297238 B1 20011002 US 2000-689943 20001012
WO 2002030908 A1 20020418 WO 2001-US42715 20011012
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL,
PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,
US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
AU 2002013485 A5 20020422 AU 2002-13485 20011012
EP 1268437 A1 20030102 EP 2001-981870 20011012
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

L37 ANSWER 55 OF 128 WPIDS COPYRIGHT 2003 THOMSON DERWENT on STN
TI Inhibiting a pro-inflammatory response of a human peripheral blood mononuclear or polymorphonuclear cell contacted with a pro-inflammatory agent, by contacting the cell with a G-protein kinase signal pathway modification agent.
PI WO 2001029069 A1 20010426 (200130)* EN 53p C07K014-00
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ
NL OA PT SD SE SL SZ TZ UG ZW
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM
DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC
LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE
SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW
AU 2000080142 A 20010430 (200148) C07K014-00
NO 2002001732 A 20020612 (200252) C07K000-00
EP 1222199 A1 20020717 (200254) EN C07K014-00
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT
RO SE SI
BR 2000014742 A 20020827 (200265) C07K014-00
KR 2002057972 A 20020712 (200305) A61K038-16
CZ 2002001342 A3 20030115 (200309) C07K014-00
HU 2002003688 A2 20030228 (200330) C07K014-00
ZA 2002002937 A 20030923 (200368) 57p C07K000-00
MX 2002003782 A1 20030101 (200373) C07K014-00
IN CLAGETT, J A; PALMER, C

L37 ANSWER 56 OF 128 WPIDS COPYRIGHT 2003 THOMSON DERWENT on STN
TI Nitrogen-containing bicyclic compounds, useful as protein kinase inhibitors for treating e.g. hyperproliferative diseases such as cancer and for promoting angiogenesis to treat e.g. ischemia, infarct or occlusion.
PI WO 2001019828 A2 20010322 (200133)* EN 139p C07D487-04
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ
NL OA PT SD SE SL SZ TZ UG ZW

W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM
 DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC
 LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE
 SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
 AU 2000074914 A 20010417 (200140) C07D487-04
 NO 2002001329 A 20020521 (200240) C07D000-00
 BR 2000014075 A 20020716 (200255) C07D487-04
 CZ 2002000934 A3 20020717 (200260) C07D487-04
 KR 2002063854 A 20020805 (200308) C07D487-04
 EP 1268481 A2 20030102 (200310) EN C07D487-04
 R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT
 RO SE SI
 JP 2003509427 W 20030311 (200319) 166p C07D471-04
 CN 1390220 A 20030108 (200334) C07D487-04
 ZA 2002002122 A 20030827 (200362) 153p C07D000-00
 SK 2002000379 A3 20030911 (200363) C07D487-04
 IN CALDERWOOD, D; HIRST, G C; RAFFERTY, P; RITTER, K; ST GALLAY, S; TWIGGER, H; TWIGGER, H L

 L37 ANSWER 57 OF 128 WPIDS COPYRIGHT 2003 THOMSON DERWENT on STN
 TI New 2-pyrazin-5-ones are serine/threonine and tyrosine kinase inhibitors, useful for treating e.g. cancer, hyperproliferative disorders, angiogenesis, inflammatory diseases and vascular hyperpermeability.
 PI WO 2001009121 A2 20010208 (200123)* EN 226p C07D403-00
 RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ
 NL OA PT SD SE SL SZ TZ UG ZW
 W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM
 DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC
 LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE
 SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
 AU 2000063889 A 20010219 (200129) C07D403-00
 NO 2002000487 A 20020312 (200232) C07D000-00
 BR 2000012896 A 20020618 (200249) C07D403-00
 CZ 2002000302 A3 20020612 (200251) C07D403-06
 EP 1218373 A2 20020703 (200251) EN C07D403-06
 R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT
 RO SE SI
 SK 2002000151 A3 20021106 (200281) C07D403-06
 CN 1377346 A 20021030 (200314) C07D403-06
 JP 2003506368 W 20030218 (200315) 379p C07D231-20
 KR 2002091829 A 20021206 (200324) A61K031-4152
 ZA 2002000477 A 20030625 (200348) 271p C07D000-00
 IN ARNOLD, L; BERLANGA, J M C; CALDERWOOD, D J; FERNANDEZ, I F; MOSET, M M; RAFFERTY, P; ARNOLD, L D; RAFFERTY, P A L

 L37 ANSWER 58 OF 128 MEDLINE on STN DUPLICATE 22
 TI Central role of p53 on regulation of **vascular permeability** factor/**vascular** endothelial growth factor (VPF/VEGF) expression in mammary carcinoma.
 SO CANCER RESEARCH, (2001 Sep 15) 61 (18) 6952-7.
 Journal code: 2984705R. ISSN: 0008-5472.
 AU Pal S; Datta K; Mukhopadhyay D
 AN 2001511700 MEDLINE

 L37 ANSWER 59 OF 128 MEDLINE on STN DUPLICATE 23
 TI Role of protein kinase Czeta in Ras-mediated transcriptional activation of **vascular permeability** factor/**vascular** endothelial growth factor expression.
 SO JOURNAL OF BIOLOGICAL CHEMISTRY, (2001 Jan 26) 276 (4) 2395-403.
 Journal code: 2985121R. ISSN: 0021-9258.
 AU Pal S; Datta K; Khosravi-Far R; Mukhopadhyay D
 AN 2001269898 MEDLINE

 L37 ANSWER 60 OF 128 SCISEARCH COPYRIGHT 2003 THOMSON ISI on STN DUPLICATE

- 24
- TI H₂O₂-mediated permeability II: importance of tyrosine phosphatase and kinase activity
- SO AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY, (DEC 2001) Vol. 281, No. 6, pp. C1940-C1947.
- Publisher: AMER PHYSIOLOGICAL SOC, 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA.
- ISSN: 0363-6143.
- AU Kevil C G; Okayama N; Alexander J S (Reprint)
- AN 2001:895466 SCISEARCH
- L37 ANSWER 61 OF 128 SCISEARCH COPYRIGHT 2003 THOMSON ISI on STN
- TI Differential regulation of diverse physiological responses to VEGF in pulmonary endothelial cells
- SO AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, (DEC 2001) Vol. 281, No. 6, pp. L1500-L1511.
- Publisher: AMER PHYSIOLOGICAL SOC, 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA.
- ISSN: 1040-0605.
- AU Becker P M (Reprint); Verin A D; Booth M A; Liu F; Birukova A; Garcia J G N
- AN 2001:910011 SCISEARCH
- L37 ANSWER 62 OF 128 SCISEARCH COPYRIGHT 2003 THOMSON ISI on STN
- TI Integrin and growth factor receptor crosstalk
- SO CIRCULATION RESEARCH, (7 DEC 2001) Vol. 89, No. 12, pp. 1104-1110.
- Publisher: LIPPINCOTT WILLIAMS & WILKINS, 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA.
- ISSN: 0009-7330.
- AU Eliceiri B P (Reprint)
- AN 2002:5860 SCISEARCH
- L37 ANSWER 63 OF 128 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
- TI Identification of anti-inflammatory Lck inhibitors that block T cell activation in vitro and in vivo.
- SO FASEB Journal, (March 8, 2001) Vol. 15, No. 5, pp. A1043. print.
- Meeting Info.: Annual Meeting of the Federation of American Societies for Experimental Biology on Experimental Biology 2001. Orlando, Florida, USA. March 31-April 04, 2001.
- CODEN: FAJOEC. ISSN: 0892-6638.
- AU Schieven, Gary [Reprint author]; Tramposch, Ken [Reprint author]; Stanley, Paul [Reprint author]; McIntyre, Kim [Reprint author]; Kanner, Steven [Reprint author]; Pang, Suhong [Reprint author]; de Fex, Henry [Reprint author]; Pitt, Sidney [Reprint author]; Shuster, David [Reprint author]; Pattoli, Mark [Reprint author]; Chen, Ping [Reprint author]; Norris, Derek [Reprint author]; Wityak, John [Reprint author]; Spergel, Steven [Reprint author]; Gu, Henry [Reprint author]; Iwanowicz, Edwin [Reprint author]; Shen, Zhongqi [Reprint author]; Lin, James [Reprint author]; Barrish, Joel [Reprint author]
- AN 2001:262558 BIOSIS
- L37 ANSWER 64 OF 128 HCAPLUS COPYRIGHT 2003 ACS on STN
- TI Synergistic effects of tumor necrosis factor- α and thrombin in increasing endothelial permeability
- SO American Journal of Physiology (2001), 281(4, Pt. 1), L958-L968
- CODEN: AJPHAP; ISSN: 0002-9513
- AU Tiruppathi, Chinnaswamy; Naqvi, Tabassum; Sandoval, Raudel; Mehta, Dolly; Malik, Asrar B.
- AN 2001:750771 HCAPLUS
- DN 136:36298
- L37 ANSWER 65 OF 128 MEDLINE on STN DUPLICATE 25
- TI The effect of treatment with albumin, hetastarch, or hypertonic saline on neurological status and brain edema in a rat model of closed

- head trauma combined with uncontrolled hemorrhage and concurrent resuscitation in rats.
- SO ANESTHESIA AND ANALGESIA, (2001 Mar) 92 (3) 669-75.
Journal code: 1310650. ISSN: 0003-2999.
- AU Eilig I; Rachinsky M; Artru A A; Alonchin A; Kapuler V; Tarnapolski A;
Shapira Y
- AN 2001159289 MEDLINE
- L37 ANSWER 66 OF 128 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
TI PECAM-1 serves as a scaffolding protein for signaling molecules in human endothelial cells.
- SO FASEB Journal, (March 7, 2001) Vol. 15, No. 4, pp. A451. print.
Meeting Info.: Annual Meeting of the Federation of American Societies for Experimental Biology on Experimental Biology 2001. Orlando, Florida, USA.
March 31-April 04, 2001.
CODEN: FAJOEC. ISSN: 0892-6638.
- AU Woolkalis, Marilyn J. [Reprint author]; Stalker, Timothy J.; Kenney,
JoAnne P.
- AN 2001:275437 BIOSIS
- L37 ANSWER 67 OF 128 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
TI Angiogenesis and chronic disease.
- SO Trends in Molecular Medicine, (August, 2001) Vol. 7, No. 8, pp. 333-334.
print.
Meeting Info.: Angiogenesis and Chronic Diseases Meeting. Keystone, CO,
USA. April 24-29, 2001.
ISSN: 1471-4914.
- AU Gerritsen, Mary E. [Reprint author]
- AN 2001:490065 BIOSIS
- L37 ANSWER 68 OF 128 MEDLINE on STN DUPLICATE 26
TI Src deficiency or blockade of Src activity in mice provides cerebral protection following stroke.
- SO NATURE MEDICINE, (2001 Feb) 7 (2) 222-7.
Journal code: 9502015. ISSN: 1078-8956.
- AU Paul R; Zhang Z G; Eliceiri B P; Jiang Q; Boccia A D; Zhang R L; Chopp M;
Cheresh D A
- AN 2001212648 MEDLINE
- L37 ANSWER 69 OF 128 MEDLINE on STN DUPLICATE 27
TI Gamma knife radiosurgery in meningiomas of the posterior fossa. Experience with 62 treated lesions.
- SO MINIMALLY INVASIVE NEUROSURGERY, (2001 Dec) 44 (4) 211-7.
Journal code: 9440973. ISSN: 0946-7211.
- AU Nicolato A; Foroni R; Pellegrino M; Ferraresi P; Alessandrini F; Gerosa M;
Bricolo A
- AN 2002132749 MEDLINE
- L37 ANSWER 70 OF 128 MEDLINE on STN
TI [Acute post-streptococcal glomerulonephritis in adults--corticosteroid therapy, yes or no?].
Akutni poststreptokokni glomerulonefritis kod odraslih--terapija kortikosteroidima, da ili ne?.
- SO VOJNOSANITETSKI PREGLED, (2001 Mar-Apr) 58 (2) 161-6.
Journal code: 21530700R. ISSN: 0042-8450.
- AU Jovanovic D; Kovacevic Z; Rabrenovic V; Skataric V
- AN 2001428675 MEDLINE
- L37 ANSWER 71 OF 128 HCPLUS COPYRIGHT 2003 ACS on STN
TI Time course of LPS-induced gene expression in a mouse model of genitourinary inflammation
- SO Physiological Genomics [online computer file] (2001), 5(3), 147-160
CODEN: PHGEFP; ISSN: 1094-8341
URL: <http://physiolgenomics.physiology.org/cgi/reprint/5/3/147>

AU Saban, Marcia R.; Hellmich, Helen; Nguyen, Ngoc-Bich; Winston, John;
Hammond, Timothy G.; Saban, Ricardo

AN 2001:464535 HCPLUS

DN 136:68190

L37 ANSWER 72 OF 128 EMBASE COPYRIGHT 2003 ELSEVIER INC. ALL RIGHTS RESERVED. on STN

TI The anthrax vaccine: A question of safety.

SO Clinical Microbiology Newsletter, (1 Apr 2001) 23/7 (51-54).

Refs: 22

ISSN: 0196-4399 CODEN: CMNEEJ

AU Snyder J.W.

AN 2001112950 EMBASE

L37 ANSWER 73 OF 128 HCPLUS COPYRIGHT 2003 ACS on STN DUPLICATE 28

TI Preparation of tricyclic pyrazole derivatives as protein kinase inhibitors.

SO PCT Int. Appl., 210 pp.

CODEN: PIXXD2

IN Doyle, Kevin J.; Rafferty, Paul; Steele, Robert W.; Wilkins, David J.;
Hockley, Michael; Arnold, Lee D.; Ericsson, Anna M.

AN 2000:335390 HCPLUS

DN 132:347566

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---------------|---|----------|-----------------|----------|
| PI | WO 2000027822 | A2 | 20000518 | WO 1999-US26105 | 19991104 |
| | WO 2000027822 | A3 | 20000810 | | |
| | W: | AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,
CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,
SK, SL, TJ, TM, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| | RW: | GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | |
| | BR 9915132 | A | 20010807 | BR 1999-15132 | 19991104 |
| | EP 1127051 | A2 | 20010829 | EP 1999-962700 | 19991104 |
| | R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO | | | |
| | JP 2003517447 | T2 | 20030527 | JP 2000-581002 | 19991104 |
| | AU 762992 | B2 | 20030710 | AU 2000-19091 | 19991104 |
| | US 6462036 | B1 | 20021008 | US 2000-573366 | 20000517 |
| | BG 105481 | A | 20011231 | BG 2001-105481 | 20010427 |
| | NO 2001002219 | A | 20010613 | NO 2001-2219 | 20010504 |
| | ZA 2001003610 | A | 20020923 | ZA 2001-3610 | 20010504 |

L37 ANSWER 74 OF 128 WPIDS COPYRIGHT 2003 THOMSON DERWENT on STN

TI Benzothiazinone and benzoxazinone protein kinase inhibitors, used e.g. to affect angiogenesis and treat hyperproliferative disorders, cancers, arthritis, atherosclerosis, psoriasis, hemangioma, **edema**, stroke and diabetes.

PI WO 2000075139 A2 20001214 (200110)* EN 183p C07D417-00

RW: AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

W: AU BG BR CA CN CZ HR HU ID IL IN JP KR MX NO NZ PL RU SG SK TR UA
US ZA

AU 2000051790 A 20001228 (200119)

EP 1181282 A2 20020227 (200222) EN C07D265-36

R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

NO 2001005899 A 20020130 (200223) C07D000-00

BR 2000011063 A 20020416 (200234) C07D417-00

CZ 2001004244 A3 20020717 (200260) C07D417-00

JP 2003501429 W 20030114 (200306) 212p C07D265-36

KR 2002062808 A 20020731 (200308) A61K031-542

IN ZA 2001009610 A 20030430 (200334) 214p C07D000-00
 ARNOLD, L D; CALDERWOOD, D; DE VEGA, M J P; FERNANDEZ, I F; MATINEZ, J L
 O; PASCUAL, B G; RAFFERTY, P; GONZALES, P B; ORTEGO, M J L; PEREZ DE VEGA,
 M J; GONZALEZ PASCUAL, B; ORTEGO MARTINEZ, J L; GONZALES, B P; ORTEGO, J L
 M; ORTEGO MATINEZ, J L

L37 ANSWER 75 OF 128 WPIDS COPYRIGHT 2003 THOMSON DERWENT on STN
 TI New substituted 1,4-Dihydroindeno(1,2-C)Pyrazoles useful in the treatment
 of e.g. cancer, arthritis and atherosclerosis are Tyrosine Kinase
 Inhibitors.

PI WO 2000059901 A1 20001012 (200062)* EN 78p C07D401-12
 RW: AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
 W: AU BG BR CA CN CZ HR HU ID IL IN JP KR MX NO NZ PL RU SG SK TR UA
 US ZA
 AU 2000040378 A 20001023 (200107) C07D401-12
 US 6297238 B1 20011002 (200160) A61K031-4162
 EP 1165544 A1 20020102 (200209) EN C07D401-12
 R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
 NO 2001004864 A 20011205 (200210) C07D000-00
 CZ 2001003580 A3 20020313 (200223) C07D495-04
 SK 2001001411 A3 20020404 (200232) C07D401-12
 BR 2000009561 A 20020416 (200234) C07D401-12
 KR 2002015034 A 20020227 (200258) C07D495-04
 HU 2002001514 A2 20020828 (200264) C07D401-12
 CN 1368970 A 20020911 (200282) C07D401-12
 JP 2002541150 W 20021203 (200309) 89p C07D231-54
 ZA 2001007838 A 20030528 (200341) 89p C07D000-00
 EP 1165544 B1 20030806 (200359) EN C07D401-12
 R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
 DE 60004340 E 20030911 (200367) C07D401-12

IN ARNOLD, L D; DOYLE, K J; RAFFERTY, P; STEELE, R W; TURNER, A; WILKINS, D
 J; ARNOLD, L; DOYLE, K; STEELE, R; WILKINS, D

L37 ANSWER 76 OF 128 WPIDS COPYRIGHT 2003 THOMSON DERWENT on STN
 TI New pyrrolo(2,3-d)pyrimidine derivatives, useful for treatment of e.g.
 angiogenesis, **vascular permeability**, immune response,
 inflammation, cancer and respiratory disorders and to decrease fertility,
 are protein kinase inhibitors.

PI WO 2000017203 A1 20000330 (200024)* EN 304p C07D487-04
 RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL
 OA PT SD SE SL SZ TZ UG ZW
 W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES
 FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS
 LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ
 TM TR TT TZ UA UG US UZ VN YU ZA ZW
 AU 9960484 A 20000410 (200035)
 NO 2001001356 A 20010516 (200137) C07D000-00
 EP 1114053 A1 20010711 (200140) EN C07D487-04
 R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT
 RO SE SI
 BR 9913887 A 20011023 (200172) C07D487-04
 CZ 2001000960 A3 20011017 (200172) C07D487-04
 KR 2001085824 A 20010907 (200218) C07D487-04
 SK 2001000384 A3 20020404 (200232) C07D487-04
 CN 1335849 A 20020213 (200233) C07D487-04
 ZA 2001002204 A 20020529 (200240) 319p C07D000-00
 HU 2002000403 A2 20020628 (200255) C07D487-04
 JP 2002526500 W 20020820 (200258) 365p C07D487-04
 AU 753555 B 20021024 (200277) C07D487-04
 MX 2001002785 A1 20011101 (200279) A61K031-505
 US 2003153752 A1 20030814 (200355) A61K031-5377
 NZ 510588 A 20030829 (200365) C07D487-04

IN ARNOLD, L D; CALDERWOOD, D; HIRST, G C; JOHNSTON, D N; MUNSCHAUER, R;
 RAFFERTY, P; FAFFERTY, P; RITTER, K; WISHART, N

- L37 ANSWER 77 OF 128 WPIDS COPYRIGHT 2003 THOMSON DERWENT on STN
 TI New pyrrolo(2,3-d)pyrimidine derivatives, useful for treatment of e.g.
 angiogenesis, **vascular permeability**, immune response,
 inflammation, cancer and respiratory disorders and to decrease fertility
 are protein kinase inhibitors.
- PI WO 2000017202 A1 20000330 (200024)* EN 242p C07D487-04
 RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL
 OA PT SD SE SL SZ TZ UG ZW
 W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES
 FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS
 LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ
 TM TR TT TZ UA UG US UZ VN YU ZA ZW
 AU 9960475 A 20000410 (200035)
 NO 2001001357 A 20010514 (200134) C07D487-04
 EP 1114052 A1 20010711 (200140) EN C07D487-04
 R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT
 RO SE SI
 CZ 2001000959 A3 20011212 (200206) C07D487-04
 BR 9913888 A 20020108 (200208) C07D487-04
 KR 2001085822 A 20010907 (200218) C07F009-44
 CN 1326457 A 20011212 (200225) C07D487-04
 ZA 2001002201 A 20020529 (200240) 272p C07D000-00
 HU 2002000355 A2 20020628 (200255) C07D487-04
 JP 2002527359 W 20020827 (200271) 257p C07D487-04
 AU 752474 B 20020919 (200272) C07D487-04
 MX 2001002784 A1 20011101 (200279) A61K031-505
 SK 2001000385 A3 20030304 (200321) C07D487-04
 US 2003187001 A1 20031002 (200365) A61K031-519

IN ARNOLD, L D; CALDERWOOD, D; DENG, B B; HIRST, G; JOHNSTON, D N;
 MAZDIYASNI, H; MUNSCHAUER, R; RAFFERTY, P; TOMETZKI, G B; TWIGGER, H L;
 HIRST, G C; ARNOLD, L; DENG, B; MAZDIYASNI, H H G

L37 ANSWER 78 OF 128 HCPLUS COPYRIGHT 2003 ACS on STN
 TI SHP2 association with VE-cadherin complexes in human endothelial cells is
 regulated by thrombin
 SO Journal of Biological Chemistry (2000), 275(8), 5983-5986
 CODEN: JBCHA3; ISSN: 0021-9258
 AU Ukropec, Jon A.; Hollinger, M. Katherine; Salva, Steven M.; Woolkalis,
 Marilyn J.
 AN 2000:156799 HCPLUS
 DN 132:277001

L37 ANSWER 79 OF 128 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
 TI Integrins, growth factors and **Src** family members in
 angiogenesis.
 SO FASEB Journal, (March 15, 2000) Vol. 14, No. 4, pp. A798. print.
 Meeting Info.: Annual Meeting of Professional Research Scientists:
 Experimental Biology 2000. San Diego, California, USA. April 15-18, 2000.
 Federation of American Societies for Experimental Biology.
 CODEN: FAJOEC. ISSN: 0892-6638.
 AU Cheresh, David A. [Reprint author]
 AN 2000:304024 BIOSIS

L37 ANSWER 80 OF 128 MEDLINE on STN
 TI The first alpha helix of interleukin (IL)-2 folds as a homotetramer, acts
 as an agonist of the IL-2 receptor beta chain, and induces
 lymphokine-activated killer cells.
 SO JOURNAL OF EXPERIMENTAL MEDICINE, (2000 Feb 7) 191 (3) 529-40.
 Journal code: 2985109R. ISSN: 0022-1007.
 AU Eckenberg R; Rose T; Moreau J L; Weil R; Gesbert F; Dubois S; Tello D;
 Bossus M; Gras H; Tartar A; Bertoglio J; Chouaib S; Goldberg M; Jacques Y;
 Alzari P M; Theze J
 AN 2000130296 MEDLINE

- L37 ANSWER 81 OF 128 MEDLINE on STN DUPLICATE 29
TI Involvement of c-Src in diperoxovanadate-induced endothelial cell barrier dysfunction.
SO AMERICAN JOURNAL OF PHYSIOLOGY. LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, (2000 Sep) 279 (3) L441-51.
Journal code: 100901229. ISSN: 1040-0605.
AU Shi S; Garcia J G; Roy S; Parinandi N L; Natarajan V
AN 2000435353 MEDLINE
- L37 ANSWER 82 OF 128 Elsevier BIOBASE COPYRIGHT 2003 Elsevier Science B.V. on STN
AN 2000219512 ESBIOBASE
TI Involvement of c-Src in diperoxovanadate-induced endothelial cell barrier dysfunction
AU Shi S.; Garcia J.G.N.; Roy S.; Parinandi N.L.; Natarajan V.
CS V. Natarajan, Johns Hopkins Asthma/Allergy Bldg., Division of Pulmonary, Critical Care Medicine, 5501 Hopkins Bayview Circle, Baltimore, MD 21224, United States.
E-mail: vnataraj@welch.jhu.edu
SO American Journal of Physiology - Lung Cellular and Molecular Physiology, (2000), 279/3 23-3 (L441-L451), 55 reference(s)
CODEN: APLPE7 ISSN: 1040-0605
DT Journal; Article
CY United States
LA English
SL English
- L37 ANSWER 83 OF 128 MEDLINE on STN DUPLICATE 30
TI NPS 1506: a novel NMDA receptor antagonist: neuroprotective effects in a model of closed head trauma in rats.
SO JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY, (2000 Oct) 12 (4) 345-55.
Journal code: 8910749. ISSN: 0898-4921.
AU Lorber A; Artru A A; Lam M A; Mueller L A; Karpas Z; Roytblat L; Shapira Y
AN 2002004881 MEDLINE
- L37 ANSWER 84 OF 128 MEDLINE on STN DUPLICATE 31
TI Role of alpha v integrins during angiogenesis.
SO CANCER JOURNAL, (2000 May) 6 Suppl 3 S245-9. Ref: 15
Journal code: 100931981. ISSN: 1528-9117.
AU Eliceiri B P; Cheresh D A
AN 2000493867 MEDLINE
- L37 ANSWER 85 OF 128 MEDLINE on STN
TI Vascular endothelial growth factor stimulates dephosphorylation of the catenins p120 and p100 in endothelial cells.
SO BIOCHEMICAL JOURNAL, (2000 Feb 15) 346 Pt 1 209-16.
Journal code: 2984726R. ISSN: 0264-6021.
AU Wong E Y; Morgan L; Smales C; Lang P; Gubby S E; Staddon J M
AN 2000125601 MEDLINE
- L37 ANSWER 86 OF 128 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
TI The mechanism by which angiopoietin 1 inhibits VEGF-mediated vascular permeability.
SO Blood, (November 16, 2000) Vol. 96, No. 11 Part 2, pp. 62b. print.
Meeting Info.: 42nd Annual Meeting of the American Society of Hematology. San Francisco, California, USA. December 01-05, 2000. American Society of Hematology.
CODEN: BLOOAW. ISSN: 0006-4971.
AU Wang, Yihong [Reprint author]; Pampou, Sergei; Varticovski, Lyuba [Reprint author]
AN 2001:312197 BIOSIS
- L37 ANSWER 87 OF 128 MEDLINE on STN DUPLICATE 32

TI Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
 SO MEDICINA, (2000) 60 Suppl 2 41-7.
 Journal code: 0204271. ISSN: 0025-7680.
 AU Wood J M
 AN 2001098649 MEDLINE

L37 ANSWER 88 OF 128 SCISEARCH COPYRIGHT 2003 THOMSON ISI on STN
 TI Oncogenes and angiogenesis: Signaling three-dimensional tumor growth
 SO JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, (DEC 2000)
 Vol. 5, No. 1, pp. 24-33.
 Publisher: BLACKWELL SCIENCE INC, 350 MAIN ST, MALDEN, MA 02148 USA.
 ISSN: 1087-0024.
 AU Rak J (Reprint); Yu J L; Klement G; Kerbel R S
 AN 2001:21036 SCISEARCH

L37 ANSWER 89 OF 128 HCAPLUS COPYRIGHT 2003 ACS on STN DUPLICATE 33
 TI Substituted tricyclic pyrazole derivatives with protein kinase inhibitory activity, and therapeutic use thereof
 SO PCT Int. Appl., 59 pp.
 CODEN: PIXXD2
 IN Arnold, Lee; Rafferty, Paul; Hockley, Michael; Turner, Allyson
 AN 1999:708607 HCAPLUS
 DN 131:317810
 PATENT NO. KIND DATE APPLICATION NO. DATE
 ----- ----- -----
 PI WO 9955335 A1 19991104 WO 1999-US9185 19990428
 W: CN, JP, US
 RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
 PT, SE
 EP 1073435 A1 20010207 EP 1999-920103 19990428
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, FI
 JP 2002512962 T2 20020508 JP 2000-545533 19990428

L37 ANSWER 90 OF 128 WPIDS COPYRIGHT 2003 THOMSON DERWENT on STN
 TI New indeno(1,2-c)pyrazole derivatives for inhibiting tyrosine kinase activity.
 PI WO 9917770 A1 19990415 (199926)* EN 44p A61K031-415
 RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL
 OA PT SD SE SZ UG ZW
 W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE
 GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG
 MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG
 US UZ VN YU ZW
 AU 9896039 A 19990427 (199936)
 EP 1021182 A1 20000726 (200037) EN A61K031-415
 R: AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT RO SE SI
 CN 1278724 A 20010103 (200124) A61K031-415
 MX 2000003359 A1 20010101 (200166) A61K031-415
 JP 2001518502 W 20011016 (200176) 48p A61K031-416
 US 6534655 B1 20030318 (200322) C07D401-04
 IN ARNOLD, L D; BARLOZZARI, T; HOCKLEY, M; RAFFERTY, P; TURNER, A; XU, Y

L37 ANSWER 91 OF 128 WPIDS COPYRIGHT 2003 THOMSON DERWENT on STN
 TI Tyrosine kinase inhibition by administration of indeno(1,2-c), naphtho(1,2-c) and benzo(6,7)cyclohepta(1,2-c)pyrazole derivatives - used as treatment for anti-hyperproliferative, anti-angiogenesis and vascular hyperpermeability disorders.
 PI WO 9917769 A1 19990415 (199923)* EN 59p A61K031-415
 RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL
 OA PT SD SE SZ UG ZW
 W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE
 GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG

MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG
US UZ VN YU ZW

AU 9896911 A 19990427 (199936) A61K031-415
EP 1023063 A1 20000802 (200038) EN A61K031-415
R: AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT RO SE SI
CN 1278725 A 20010103 (200124) A61K031-415
MX 2000003360 A1 20010101 (200166) A61K031-415
JP 2001518501 W 20011016 (200176) 73p A61K031-416
US 6451834 B1 20020917 (200264) A61K031-415
EP 1023063 B1 20030910 (200360) EN A61K031-415
R: AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT RO SE SI
IN ARNOLD, L D; BARLOZZARI, T; XU, Y

L37 ANSWER 92 OF 128 MEDLINE on STN DUPLICATE 34
TI Regulation of endothelial cell myosin light chain kinase by Rho,
cortactin, and p60(**src**).
SO AMERICAN JOURNAL OF PHYSIOLOGY, (1999 Jun) 276 (6 Pt 1) L989-98.
Journal code: 0370511. ISSN: 0002-9513.
AU Garcia J G; Verin A D; Schaphorst K; Siddiqui R; Patterson C E; Csortos C;
Natarajan V
AN 1999292446 MEDLINE

L37 ANSWER 93 OF 128 SCISEARCH COPYRIGHT 2003 THOMSON ISI on STN
TI Regulation of endothelial cell myosin light chain kinase by Rho,
cortactin, and p60(**src**)
SO AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY,
(JUN 1999) Vol. 20, No. 6, pp. L989-L998.
Publisher: AMER PHYSIOLOGICAL SOC, 9650 ROCKVILLE PIKE, BETHESDA, MD
20814.
ISSN: 1040-0605.
AU Garcia J G N (Reprint); Verin A D; Schaphorst K; Siddiqui R; Patterson C
E; Csortos C; Natarajan V
AN 1999:467611 SCISEARCH

L37 ANSWER 94 OF 128 Elsevier BIOBASE COPYRIGHT 2003 Elsevier Science B.V.
on STN
AN 1999157877 ESBIOBASE
TI Regulation of endothelial cell myosin light chain kinase by Rho,
cortactin, and p60(**src**)
AU Garcia J.G.N.; Verin A.D.; Schaphorst K.; Siddiqui R.; Patterson C.E.;
Csortos C.; Natarajan V.
CS J.G.N. Garcia, 5501 Hopkins Bayview Circle, Baltimore, MD 21224, United
States.
E-mail: drgarcia@welchlink.welch.jhu.edu
SO American Journal of Physiology - Lung Cellular and Molecular Physiology,
(1999), 276/6 20-6 (L989-L998), 54 reference(s)
CODEN: APLPE7 ISSN: 1040-0605
DT Journal; Article
CY United States
LA English
SL English

L37 ANSWER 95 OF 128 MEDLINE on STN DUPLICATE 35
TI Treatments to support blood pressure increases bleeding and/or decreases
survival in a rat model of closed head trauma combined with uncontrolled
hemorrhage.
SO ANESTHESIA AND ANALGESIA, (1999 Oct) 89 (4) 950-6.
Journal code: 1310650. ISSN: 0003-2999.
AU Talmor D; Merkind V; Artru A A; Shapiro O; Geva D; Roytblat L; Shapira Y
AN 1999440822 MEDLINE

L37 ANSWER 96 OF 128 MEDLINE on STN DUPLICATE 36
TI Selective requirement for **Src** kinases during VEGF-induced
angiogenesis and **vascular permeability**.

- SO MOLECULAR CELL, (1999 Dec) 4 (6) 915-24.
 Journal code: 9802571. ISSN: 1097-2765.
 AU Eliceiri B P; Paul R; Schwartzberg P L; Hood J D; Leng J; Cheresh D A
 AN 2000101234 MEDLINE
- L37 ANSWER 97 OF 128 EMBASE COPYRIGHT 2003 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
 TI Immunohistological study of endothelin-1 and endothelin-A and B receptors in two patients with scleroderma renal crisis.
 SO Clinical Rheumatology, (1999) 18/5 (425-427).
 Refs: 10
 ISSN: 0770-3198 CODEN: CLRHD6
 AU Kobayashi H.; Nishimaki T.; Kaise S.; Suzuki T.; Watanabe K.; Kasukawa R.; Suzuki T.
 AN 1999356183 EMBASE
- L37 ANSWER 98 OF 128 SCISEARCH COPYRIGHT 2003 THOMSON ISI on STN
 TI An unusual form of neurosarcoidosis with intracranial mass lesion, chronic meningitis, hydrocephalus and hypothalamic dysfunction
 SO NEUROCHIRURGIE, (SEP 1999) Vol. 45, No. 3, pp. 243-246.
 Publisher: MASSON EDITEUR, 120 BLVD SAINT-GERMAIN, 75280 PARIS 06, FRANCE.
 ISSN: 0028-3770.
 AU Series C (Reprint); Jarnier D; Cohadon F; Loiseau H; Guez S
 AN 1999:838067 SCISEARCH
- L37 ANSWER 99 OF 128 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
 TI The role of cortactin in thrombin-induced endothelial cell stress fiber formation.
 SO Journal of Investigative Medicine, (Aug., 1999) Vol. 47, No. 7, pp. 218A.
 print.
 Meeting Info.: Meeting of the American Federation for Medical Research,
 Midwestern Regional. Chicago, Illinois, USA. September 16-18, 1999.
 American Federation for Medical Research.
 ISSN: 1081-5589.
 AU Dudek, S. M. [Reprint author]; Birukov, K. [Reprint author]; Zhan, X.
 [Reprint author]; Garcia, J. G. N. [Reprint author].
 AN 1999:440646 BIOSIS
- L37 ANSWER 100 OF 128 HCAPLUS COPYRIGHT 2003 ACS on STN
 TI Identification of enantiomeric ligands
 SO U.S., 20 pp., Cont.-in-part of U.S. Ser. No. 482,309, abandoned.
 CODEN: USXXAM
 IN Schumacher, Antonius Nicolass Maria; Kim, Peter S.
 AN 1998:478969 HCAPLUS
 DN 129:133389
- | | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|--|------|----------|-----------------|----------|
| PI | US 5780221 | A | 19980714 | US 1996-627497 | 19960328 |
| | CA 2218083 | AA | 19961107 | CA 1996-2218083 | 19960502 |
| | WO 9634879 | A1 | 19961107 | WO 1996-US6155 | 19960502 |
| | W: CA, JP, US | | | | |
| | RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE | | | | |
| | EP 825997 | A1 | 19980304 | EP 1996-915457 | 19960502 |
| | R: DE, FR, GB, NL | | | | |
| | JP 11505527 | T2 | 19990521 | JP 1996-533492 | 19990521 |
- L37 ANSWER 101 OF 128 SCISEARCH COPYRIGHT 2003 THOMSON ISI on STN
 TI Activation of Sp1-mediated **vascular permeability** factor/**vascular** endothelial growth factor transcription requires specific interaction with protein kinase C zeta
 SO JOURNAL OF BIOLOGICAL CHEMISTRY, (9 OCT 1998) Vol. 273, No. 41, pp. 26277-26280.
 Publisher: AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC, 9650 ROCKVILLE PIKE, BETHESDA, MD 20814.

- ISSN: 0021-9258.
AU Pal S; Claffey P; Cohen H T; Mukhopadhyay D (Reprint)
AN 1998:793797 SCISEARCH
- L37 ANSWER 102 OF 128 MEDLINE on STN DUPLICATE 37
TI Phenylephrine-induced hypertension does not improve outcome after closed head trauma in rats.
SO ANESTHESIA AND ANALGESIA, (1998 Sep) 87 (3) 574-8.
Journal code: 1310650. ISSN: 0003-2999.
AU Talmor D; Roytblat L; Artru A A; Yuri O; Koyfman L; Katchko L; Shapira Y
AN 1998397032 MEDLINE
- L37 ANSWER 103 OF 128 MEDLINE on STN DUPLICATE 38
TI Development of transgenic Xenopus laevis with a high C-**src** gene expression.
SO MOLECULAR REPRODUCTION AND DEVELOPMENT, (1998 Aug) 50 (4) 410-9.
Journal code: 8903333. ISSN: 1040-452X.
AU Takac M; Habrova V; Macha J; Ceskova N; Jonak J
AN 1998332188 MEDLINE
- L37 ANSWER 104 OF 128 LIFESCI COPYRIGHT 2003 CSA on STN DUPLICATE 39
TI Studies on the role of c-**Src** protein tyrosine kinase in the expression of toxicity of TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin
SO Reviews in Toxicology, (19980000) vol. 2, no. 1-4, pp. 73-83.
Meeting Info.: Pesticides and the Future: Minimizing Exposure of Humans and the Environment. Kisarazu (Japan). 26-30 May 1997.
ISSN: 1382-6980.
AU Matsumura, Fumio; Enan, E.; Dunlap, D.Y.; Ashida, Hitoshi; Olsen, H.; Hwang, Seong-Gu; Wu, Zhong
AN 1999:27075 LIFESCI
- L37 ANSWER 105 OF 128 MEDLINE on STN DUPLICATE 40
TI Mechanical stretch induces **vascular permeability** factor in human mesangial cells: mechanisms of signal transduction.
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (1997 Oct 28) 94 (22) 12112-6.
Journal code: 7505876. ISSN: 0027-8424.
AU Gruden G; Thomas S; Burt D; Lane S; Chusney G; Sacks S; Viberti G
AN 1998004532 MEDLINE
- L37 ANSWER 106 OF 128 HCPLUS COPYRIGHT 2003 ACS on STN
TI Value of different modalities of granulocyte-macrophage colony-stimulating factor applied during or after induction therapy of acute myeloid leukemia
SO Journal of Clinical Oncology (1997), 15(12), 3496-3506
CODEN: JCONDN; ISSN: 0732-183X
AU Lowenberg, B.; Boogaerts, M. A.; Daenen, S. M. G. J.; Verhoef, G. E. G.; Hagenbeek, A.; Vellenga, E.; Ossenkoppele, G. J.; Huijgens, P. C.; Verdonck, L. F.; van der Lelie, J.; Wielenga, J. J.; Schouten, H. C.; Gmur, J.; Gratwohl, A.; Hess, U.; Fey, M. F.; van Putten, W. L. J.
AN 1997:810937 HCPLUS
DN 128:110559
- L37 ANSWER 107 OF 128 HCPLUS COPYRIGHT 2003 ACS on STN
TI Tumor angiogenesis and Flt tyrosine kinase
SO Tanpakushitsu Kakusan Koso (1997), 42(10), 1470-1476
CODEN: TAKKAJ; ISSN: 0039-9450
AU Shibuya, Masabumi
AN 1997:464492 HCPLUS
DN 127:107276
- L37 ANSWER 108 OF 128 MEDLINE on STN DUPLICATE 41
TI Altered in vivo toxicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in C-**src** deficient mice.
SO BIOCHEMICAL PHARMACOLOGY, (1997 May 15) 53 (10) 1397-404.

- Journal code: 0101032. ISSN: 0006-2952.
- AU Matsumura F; Enan E; Dunlap D Y; Pinkerton K E; Peake J
AN 97405821 MEDLINE
- L37 ANSWER 109 OF 128 SCISEARCH COPYRIGHT 2003 THOMSON ISI on STN
TI Reciprocal relation between VEGF and NO in the regulation of endothelial integrity
SO NATURE MEDICINE, (AUG 1997) Vol. 3, No. 8, pp. 879-886.
Publisher: NATURE PUBLISHING CO, 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707.
ISSN: 1078-8956.
AU Tsurumi Y; Murohara T; Krasinski K; Chen D F; Witzenbichler B; Kearney M;
Couffinhal T; Isner J M (Reprint)
AN 97:591499 SCISEARCH
- L37 ANSWER 110 OF 128 MEDLINE on STN DUPLICATE 42
TI Brain **edema**, hemorrhagic necrosis volume, and neurological status with rapid infusion of 0.45% saline or 5% dextrose in 0.9% saline after closed head trauma in rats.
SO ANESTHESIA AND ANALGESIA, (1997 Mar) 84 (3) 554-9.
Journal code: 1310650. ISSN: 0003-2999.
AU Gurevich B; Talmor D; Artru A A; Katcko L; Geva D; Gurman G; Shapira Y
AN 97204792 MEDLINE
- L37 ANSWER 111 OF 128 HCAPLUS COPYRIGHT 2003 ACS on STN
TI Apparent antinociceptive and anti-inflammatory effects of GYKI 52466
SO European Journal of Pharmacology (1997), 336(2/3), 143-154
CODEN: EJPHAZ; ISSN: 0014-2999
AU Szekely, Jozsef I.; Kedves, Rita; Mate, Ildiko; Toeroek, Katalin; Tarnawa, Istvan
AN 1997:646583 HCAPLUS
DN 127:341510
- L37 ANSWER 112 OF 128 SCISEARCH COPYRIGHT 2003 THOMSON ISI on STN
TI INCREASE OF PROTEIN-TYROSINE PHOSPHORYLATION IN RAT RETINA AFTER ISCHEMIA-REPERFUSION INJURY
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, (OCT 1996) Vol. 37, No. 11, pp. 2146-2156.
ISSN: 0146-0404.
AU HAYASHI A; KOROMA B M; IMAI K; DEJUAN E (Reprint)
AN 96:732571 SCISEARCH
- L37 ANSWER 113 OF 128 MEDLINE on STN DUPLICATE 43
TI Depletion of [Ca²⁺]_i inhibits hypoxia-induced **vascular permeability factor** (**vascular** endothelial growth factor) gene expression.
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, (1996 Dec 24) 229 (3) 733-8.
Journal code: 0372516. ISSN: 0006-291X.
AU Mukhopadhyay D; Akbarali H I
AN 97115650 MEDLINE
- L37 ANSWER 114 OF 128 SCISEARCH COPYRIGHT 2003 THOMSON ISI on STN
TI HIGH-INFLATION PRESSURE AND POSITIVE END-EXPIRATORY PRESSURE - INJURIOUS TO THE LUNG - **YES**
SO CRITICAL CARE CLINICS, (JUL 1996) Vol. 12, No. 3, pp. 627.
ISSN: 0749-0704.
AU PAPADAKOS P J (Reprint); APOSTOLAKOS M J
AN 96:579669 SCISEARCH
- L37 ANSWER 115 OF 128 MEDLINE on STN DUPLICATE 44
TI Controversies in magnetic resonance imaging of the hip.
SO TOPICS IN MAGNETIC RESONANCE IMAGING, (1996 Feb) 8 (1) 44-50. Ref: 27
Journal code: 8913523. ISSN: 0899-3459.

- AU MacDougall L; Conway W F
AN 96417302 MEDLINE
- L37 ANSWER 116 OF 128 MEDLINE on STN DUPLICATE 45
TI Wild-type p53 and v-Src exert opposing influences on human
vascular endothelial growth factor gene expression.
SO CANCER RESEARCH, (1995 Dec 15) 55 (24) 6161-5.
Journal code: 2984705R. ISSN: 0008-5472.
AU Mukhopadhyay D; Tsiokas L; Sukhatme V P
AN 96105036 MEDLINE
- L37 ANSWER 117 OF 128 MEDLINE on STN DUPLICATE 46
TI Hypoxic induction of human vascular endothelial growth factor expression
through c-Src activation.
SO NATURE, (1995 Jun 15) 375 (6532) 577-81.
Journal code: 0410462. ISSN: 0028-0836.
AU Mukhopadhyay D; Tsiokas L; Zhou X M; Foster D; Brugge J S; Sukhatme V P
AN 95312075 MEDLINE
- L37 ANSWER 118 OF 128 MEDLINE on STN DUPLICATE 47
TI Oncogenes as inducers of tumor angiogenesis.
SO CANCER AND METASTASIS REVIEWS, (1995 Dec) 14 (4) 263-77. Ref: 85
Journal code: 8605731. ISSN: 0891-9992.
AU Rak J; Filmus J; Finkenzeller G; Grugel S; Marme D; Kerbel R S
AN 96418305 MEDLINE
- L37 ANSWER 119 OF 128 SCISEARCH COPYRIGHT 2003 THOMSON ISI on STN
TI ONCOGENES AS INDUCERS OF TUMOR ANGIOGENESIS
SO CANCER AND METASTASIS REVIEWS, (DEC 1995) Vol. 14, No. 4, pp. 263-277.
ISSN: 0167-7659.
AU RAK J; FILMUS J; FINKENZELLER G; GRUGEL S; MARME D; KERBEL R S (Reprint)
AN 96:89542 SCISEARCH
- L37 ANSWER 120 OF 128 SCISEARCH COPYRIGHT 2003 THOMSON ISI on STN
TI PROTEIN-TYROSINE KINASES EXPRESSED IN GLOMERULI AND CULTURED GLOMERULAR
CELLS - FLT-1 AND VEGF EXPRESSION IN RENAL MESANGIAL CELLS
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, (06 APR 1995) Vol.
209, No. 1, pp. 218-226.
ISSN: 0006-291X.
AU TAKAHASHI T; SHIRASAWA T (Reprint); MIYAKE K; YAHAGI Y; MARUYAMA N;
KASAHIKA N; KAWAMURA T; MATSUMURA O; MITARAI T; SAKAI O
AN 95:261587 SCISEARCH
- L37 ANSWER 121 OF 128 SCISEARCH COPYRIGHT 2003 THOMSON ISI on STN
TI SIGNALING PROPERTIES OF FLT4, A PROTEOLYTICALLY PROCESSED RECEPTOR
TYROSINE KINASE RELATED TO 2 VEGF RECEPTORS
SO ONCOGENE, (DEC 1994) Vol. 9, No. 12, pp. 3545-3555.
ISSN: 0950-9232.
AU PAJUSOLA K; APRELIKHOVA O; PELICCI G; WEICH H; CLAESSENWELSH L; ALITALO K
(Reprint)
AN 94:751615 SCISEARCH
- L37 ANSWER 122 OF 128 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
TI Transfer of rous sarcoma virus DNA to ova by Xenopus laevis spermatozoa.
SO Cell Biology International, (1994) Vol. 18, No. 5, pp. 465.
Meeting Info.: IVth European Cell Biology Congress. Prague, Czech
Republic. June 26-July 1, 1994.
ISSN: 1065-6995.
AU Jonak, J. [Reprint author]; Habrova, V.; Takac, M. [Reprint author];
Macha, J.; Reinis, M. [Reprint author]; Pokorna, H.
AN 1994:419782 BIOSIS
- L37 ANSWER 123 OF 128 MEDLINE on STN
TI Key assessment and classification elements of the WHO / UNICEF sick child

- algorithm.
- SO QA Brief, (1994 Jan) 3 (1) 19.
Journal code: 101084259.
Report No.: PIP-093901; POP-00230422.
- AU Anonymous
AN 2002555160 MEDLINE
- L37 ANSWER 124 OF 128 MEDLINE on STN
TI Heterogeneity of hypertrophy in feline hypertrophic heart disease.
SO JOURNAL OF VETERINARY INTERNAL MEDICINE, (1993 May-Jun) 7 (3) 183-9.
Journal code: 8708660. ISSN: 0891-6640.
AU Peterson E N; Moise N S; Brown C A; Erb H N; Slater M R
AN 93323058 MEDLINE
- L37 ANSWER 125 OF 128 EMBASE COPYRIGHT 2003 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
TI Perioperative nonspecific histamine release: A new classification by aetiological mechanisms and evaluation of their clinical relevance.
SO Annales Francaises d'Anesthesie et de Reanimation, (1993) 12/2 (147-165).
ISSN: 0750-7658 CODEN: AFAREO
AU Duda D.; Lorenz W.; Menke H.; Stinner B.; Hasse C.; Nies C.; Schafer U.;
Sitter H.; Junginger T.; Rothmund M.; Doenicke A.; Dick W.
AN 93176428 EMBASE
- L37 ANSWER 126 OF 128 MEDLINE on STN DUPLICATE 48
TI Radiotherapy in T1 laryngeal cancer: prognostic factors for locoregional control and survival, uni- and multivariate analysis.
SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY, BIOLOGY, PHYSICS, (1991 Oct) 21 (5) 1179-86.
Journal code: 7603616. ISSN: 0360-3016.
AU Terhaard C H; Snippe K; Ravasz L A; van der Tweel I; Hordijk G J
AN 92041108 MEDLINE
- L37 ANSWER 127 OF 128 MEDLINE on STN
TI [Radial keratotomy? Yes, but.... Apropos of 3 serious complications].
Keratotomie radiaire? Oui, mais.... A propos de trois complications graves.
SO BULLETIN DE LA SOCIETE BELGE D OPHTALMOLOGIE, (1989) 234 9-14.
Journal code: 7505353. ISSN: 0081-0746.
AU Meur G
AN 91077565 MEDLINE
- L37 ANSWER 128 OF 128 MEDLINE on STN
TI Special uses for captopril.
SO AMERICAN JOURNAL OF KIDNEY DISEASES, (1987 Jul) 10 (1 Suppl 1) 88-93.
Ref: 51
Journal code: 8110075. ISSN: 0272-6386.
AU Materson B J
AN 87267603 MEDLINE
- =>
=> d ab 89-90,96,104,105,108,109,112,120,121
- L37 ANSWER 89 OF 128 HCPLUS COPYRIGHT 2003 ACS on STN DUPLICATE 33
AB Chemical compds. that are derivs. of 2H[1]-benzothiepino[5,4-c]pyrazole, 2H[1]-benzoxepino[5,4-c]pyrazole, 1-benzothiopyrano[4,3-c]pyrazole, 1-benzopyrano[4,3-c]pyrazole, 4,5-dihydro-2H-furano[2,3-g]indazole and 4,5-dihydro-2H-thieno[2,3-g]indazole derivs., 2H[1]-benzothiepino[5,4-c]pyrazole, [1]-benzothiopyrano[4,3-c]pyrazole, 4,5-dihydro-2H-furano[2,3-g]indazole and 4,5-dihydro-2H-thieno[2,3-g]indazole derivs. are inhibitors of protein kinase activity. Several of the protein kinases, whose activity is inhibited by these chemical compds., are involved in angiogenic

and/or **edematous** processes. Thus, these chemical compds. can ameliorate disease states where angiogenesis, **edema** or endothelial cell hyperproliferation or hyperpermeability is a factor. The diseases include cancer, arthritis, atherosclerosis, psoriasis, hemangioma, myocardial angiogenesis, coronary and cerebral collaterals, ischemic limb angiogenesis, corneal disease, rubeosis, neovascular glaucoma, macular degeneration, wound healing, peptic ulcer Helicobacter related diseases, fractures, diabetic retinopathy, and cat scratch fever.

- L37 ANSWER 90 OF 128 WPIDS COPYRIGHT 2003 THOMSON DERWENT on STN
AB WO 9917770 A UPAB: 19990707
NOVELTY - Indeno(1,2-c)pyrazole derivatives (I) for inhibiting tyrosine kinase activity.
DETAILED DESCRIPTION - Inhibiting tyrosine kinase activity comprises administration of indeno(1,2-c)pyrazole derivatives of formula (I):
X = CO or optionally substituted methylene;
R1 = H or Me;
R2 = pyridyl or optionally substituted phenyl;
provided that: when X = CH₂ then R1 = Me.
ACTIVITY - Antiangiogenic; antidiabetic; antiarthritic; antipsoriatic; antiulcer; ophthalmological; antifertility.
MECHANISM OF ACTION - Tyrosine kinase inhibitors.
USE - For inhibiting tyrosine kinase, preferably a receptor or non-receptor tyrosine kinase, particularly KDR, ftt-1, TIE-2, Lek, **Src**, fyn or **yes** or a tyrosine kinase which affects angiogenesis or vascular hyperpermeability. (I) can be used to treat fibrosis and diabetes and can ameliorate disease states where angiogenesis or endothelial cell proliferation is a factor and also inhibit induction of vascular hyperpermeability and associated formation of **edema**, ascites and exudates. (I) are active against arthritis, atherosclerosis, psoriasis, hemangiomas, myocardial angiogenesis, coronary and cerebral collateral vascularization, ischemic limb angiogenesis, wound healing, peptic ulcer, Helicobacter related diseases, fractures, cat scratch fever, rubeosis, corneal diseases, neovascular glaucoma and retinopathies such as those associated with diabetic retinopathy or macular degeneration or similar disease states dependent on angiogenesis supported blood and nutrient supply or on endothelial cell hyperproliferative disorders. Some (I) are antifertility agents and abortifacients. N-methylated analogs of (I) are prodrugs acting as metabolically activated angiogenic agents.
ADVANTAGE - By inhibition of kinase activity of VEGr receptors, hyperpermeability as well as associated extravasation, **edema** or ascites formation and matrix deposition is inhibited and minimized.

- L37 ANSWER 96 OF 128 MEDLINE on STN DUPLICATE 36
AB **Src** kinase activity was found to protect endothelial cells from apoptosis during vascular endothelial growth factor (VEGF)-, but not basic fibroblast growth factor (bFGF)-, mediated angiogenesis in chick embryos and mice. In fact, retroviral targeting of kinase-deleted **Src** to tumor-associated blood vessels suppressed angiogenesis and the growth of a VEGF-producing tumor. Although mice lacking individual **Src** family kinases (SFKs) showed normal angiogenesis, mice deficient in pp60c-**src** or pp62c-**yes** showed no VEGF-induced **vascular permeability** (VP), yet fyn-/- mice displayed normal VP. In contrast, inflammation-mediated VP appeared normal in **Src**-deficient mice. Therefore, VEGF-, but not bFGF-, mediated angiogenesis requires SFK activity in general, whereas the VP activity of VEGF specifically depends on the SFKs, **Src**, or **Yes**.

- L37 ANSWER 104 OF 128 LIFESCI COPYRIGHT 2003 CSA on STN DUPLICATE 39
AB Dioxin is said to be the most toxic man made chemical ever known. Yet, the toxic action mechanisms for this group of chemicals, other than initial binding to the Ah receptor and subsequent transcriptional activation of certain genes, remain largely unknown. In this article we describe the results of our research efforts over the past 15 years to show why TCDD

causes a spectacular rise in the activity of protein tyrosine kinases and how such a phenomenon is related to its expression of toxicity. The pursuit of the former question led to the discovery of c-Src kinase (pp60 super(c-src)) as being the kinase directly associated with the Ah receptor and being the one immediately activated upon TCDD binding to this receptor. More recently we could test this hypothesis in vivo by studying the effects of a single dose of TCDD (115 µg/kg i.p.) on c-src knockout mice in comparison with the wild type littermates. We found that many of the hallmark effects of TCDD, such as body weight loss, reduction in the weight of adipose tissue, pancreas and heart, thymic involution, and fatty infiltration of the liver, etc., were absent from these c-src deficient mice, while the enlargement of liver (hepatomegaly), induction of cytochrome P450, formation of liver edema, etc., were not affected at all by this genetic manipulation. c-Src kinase appears to play a crucial role in the expression of the toxic effects of TCDD.

L37 ANSWER 105 OF 128 MEDLINE on STN DUPLICATE 40
AB Hemodynamic abnormalities have been implicated in the pathogenesis of the increased glomerular permeability to protein of diabetic and other glomerulopathies. **Vascular permeability** factor (VPF) is one of the most powerful promoters of **vascular permeability**. We studied the effect of stretch on VPF production by human mesangial cells and the intracellular signaling pathways involved. The application of mechanical stretch (elongation 10%) for 6 h induced a 2.4-fold increase over control in the VPF mRNA level ($P < 0.05$). There was a corresponding 3-fold increase in VPF protein level by 12 h ($P < 0.001$), returning to the baseline by 24 h. Stretch-induced VPF secretion was partially prevented both by the protein kinase C (PKC) inhibitor H7 (50 µM: 72% inhibition, $P < 0.05$) and by pretreatment with phorbol ester (phorbol-12-myristate-13 acetate 10(-)7 M: 77% inhibition, $P < 0.05$). A variety of protein tyrosine kinase (PTK) inhibitors, genistein (20 µg/ml), herbimycin A (3.4 µM), and a specific pp60(src) peptide inhibitor (21 µM) also significantly reduced, but did not entirely prevent, stretch-induced VPF protein secretion (respectively 63%, 80%, and 75% inhibition; $P < 0.05$ for all). The combination of both PKC and PTK inhibition completely abolished the VPF response to mechanical stretch (100% inhibition, $P < 0.05$). Stretch induces VPF gene expression and protein secretion in human mesangial cells via PKC- and PTK-dependent mechanisms.

L37 ANSWER 108 OF 128 MEDLINE on STN DUPLICATE 41
AB Administration of a single i.p. dose of 115 µg/kg of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) to homozygous and heterozygous c-src deficient mice (i.e. c-src -/- and -/+ mice) and their wild-type littermates (c-src +/+ mice) induced differential toxic responses. In c-src +/+ mice, there were clear-cut signs of the toxicity of TCDD, such as the loss of weight in the body, thymus and adipose tissue, whereas in c-src -/+ mice these effects were modest and were not statistically significant. Yet, hepatomegaly, a characteristic effect of TCDD, took place in all three strains of mice. Histological examination of liver samples from control mice and from mice treated with TCDD for 10 days showed that there are qualitative differences in the expression of the effects of TCDD between control and treated mice as well as between c-src -/+ and +/+ mice. In the case of c-src +/+ mice, the predominant lesions were lipid accumulation, glycogen depletion, edema formation and necrosis, as shown by the presence of large areas of ballooning degeneration, and cellular influx of fluid. These changes were demonstrated only marginally in c-src -/+ mice. The predominant effect in -/+ mice was edema formation. At a high dose of TCDD (345 µg/kg), all of the +/+ mice died within 34 days, whereas none of the c-src -/+ mice died. Together these results clearly indicate that some of the toxic effects of TCDD are not fully expressed in

c-src deficient mice.

L37 ANSWER 109 OF 128 SCISEARCH COPYRIGHT 2003 THOMSON ISI on STN

AB Balloon angioplasty disrupts the protective endothelial lining of the arterial wall, rendering arteries susceptible to thrombosis and intimal thickening. We show here that Vascular endothelial growth factor (VEGF), an endothelial cell mitogen, is upregulated in medial smooth muscle cells of the arterial wall in response to balloon injury. Both protein kinase C (PKC) and tyrosine kinase pp60(**src**) mediate augmented VEGF expression. In contrast, nitric oxide (NO) donors inhibit PKC-induced VEGF upregulation by interfering with binding of the transcription factor activator protein-1 (AP-1) to the VEGF promoter. Inhibition of VEGF promoter activation suggests that NO secreted by a restored endothelium functions as the negative feedback mechanism that downregulates VEGF expression to basal levels. Administration of a neutralizing VEGF antibody impaired reendothelialization following balloon injury performed *in vivo*. These findings establish a reciprocal relation between VEGF and NO in the endogenous regulation of endothelial integrity following arterial injury.

L37 ANSWER 112 OF 128 SCISEARCH COPYRIGHT 2003 THOMSON ISI on STN

AB Purpose. This study was conducted to examine the effect of retinal ischemia-reperfusion injury on protein tyrosine phosphorylation, the production of angiogenic growth factors, and the activation of signal proteins in tyrosine kinase pathways.

Methods. Ischemia-reperfusion injury was induced in rats by compression of the optic nerve for 2 hours. The rats were killed, and the retinas were collected at 0, 1, 6, 24, 48, 96, or 168 hours of reperfusion. Tyrosine phosphorylation of proteins in the retina was examined by Western blot analysis and immunohistochemistry. Angiogenic growth factors and their receptors, such as basic fibroblast growth factor (bFGF) and Flg, vascular endothelial growth factor (VEGF) and Flk-1, platelet-derived growth factor (PDGF)-B chain and PDGF-beta receptor, and five intracellular signal proteins (phosphatidylinositol 3-kinase [PI3K], phospholipase C gamma [PLC gamma], C-Src, SHC, and mitogen-activated protein kinase [MAPK]) were examined by Western blot analysis.

Results. Protein tyrosine phosphorylation increased after ischemia-reperfusion injury, reaching a peak at 48 hours of reperfusion. Increased staining of tyrosine-phosphorylated proteins in the inner retina were evident on immunohistochemical examination. The amount of bFGF decreased after injury, but the amounts of VEGF and PDGF-B chain increased. Tyrosine phosphorylation of PLC gamma, SHC, and MAPK was increased at 48 hours of reperfusion, and tyrosine phosphorylation of PDGF-beta receptor and PI3K was increased at 168 hours of reperfusion.

Conclusions. Ischemia-reperfusion injury in the rat retina leads to activation of the tyrosine kinase pathway, increasing the amounts of angiogenic growth factors. The resultant activation of signal proteins PLC gamma, SHC, MAPK, PI3K, and PDGF-beta receptor may play an important role in ischemia-induced retinal changes such as cell proliferation.

L37 ANSWER 120 OF 128 SCISEARCH COPYRIGHT 2003 THOMSON ISI on STN

AB Protein tyrosine kinases play an important role in cellular proliferation and differentiation of various cell types. To identify potential tyrosine kinases involved in glomerular functions we have utilized the polymerase chain reaction (PCR) and degenerate oligonucleotides for isolation of such genes from isolated glomeruli, cultured mesangial cell, and glomerular endothelial cells. Sequence analysis of PCR-amplified cDNAs resulted in the isolation of 24 tyrosine kinases. Here we describe for the first time the constitutive expression of 15 tyrosine kinases, tyro-1, tyro-4, tyro-6, hyk, Ptk-3, Ryk, tie, yes, lyn, tee, Jak1, Jak2, Jak3, c-abl, and flk, in renal glomeruli. in addition, Flt-1, an endothelial cell-specific receptor for vascular endothelial growth factor (VEGF), is expressed in renal mesangial cells and its gene expression is up-regulated upon the stimulation of platelet-derived growth factor (PDGF) with the concomitant up-regulation

of VEGF. These data suggest the possible involvement of VEGF/Flt-1 system in cytokine-induced mesangial cell proliferations. (C) 1995 Academic Press, Inc.

L37 ANSWER 121 OF 128 SCISEARCH COPYRIGHT 2003 THOMSON ISI on STN
AB The FLT4, FLT1 and KDR/FLK1 genes encode, structurally similar endothelial cell receptor tyrosine kinases. Recently it has been shown that the FLT1 and KDR/FLK-1 proteins function as high-affinity receptors for vascular endothelial growth factor (VEGF). Here we show that FLT4 does not act as a receptor for VEGF, as VEGF did not show specific binding to the FLT4 tyrosine kinase or induce its autophosphorylation. Also, FLT4 did not interact with KDR in response to VEGF. However, when fused with the ligand binding domain of the colony stimulating factor-1 receptor (CSF-1R), the FLT4 tyrosine kinase was specifically activated by CSF-1. The activated FLT4 tyrosine kinase domain was found to interact with the **Src** homology 2 domains of the SHC and GRB2 adaptor proteins in vitro and with SHC in cells. CSF-1 stimulation of the CSF-1R/FLT4 receptor chimera induced thymidine incorporation in serum-starved NIH3T3 fibroblasts, but not in porcine aortic or murine lung capillary endothelial cells, although tyrosyl phosphorylation of the receptor and SHC occurred in these cells as well. These results suggest that the endothelial cell FLT4 receptor tyrosine kinase transmits signals for an as yet unidentified growth factor.

=> log y
COST IN U.S. DOLLARS

| | SINCE FILE ENTRY | TOTAL SESSION |
|---------------------|------------------|---------------|
| FULL ESTIMATED COST | 257.89 | 260.20 |

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

| | SINCE FILE ENTRY | TOTAL SESSION |
|---------------------|------------------|---------------|
| CA SUBSCRIBER PRICE | -0.65 | -0.65 |

STN INTERNATIONAL LOGOFF AT 15:55:32 ON 18 NOV 2003